273 lines
185 KiB
Text
273 lines
185 KiB
Text
<!DOCTYPE html>
|
|
<html xmlns="http://www.w3.org/1999/xhtml" xml:lang="en" class="no-js no-jr">
|
|
<head>
|
|
<!-- For pinger, set start time and add meta elements. -->
|
|
<script type="text/javascript">var ncbi_startTime = new Date();</script>
|
|
|
|
<!-- Logger begin -->
|
|
<meta name="ncbi_db" content="books">
|
|
<meta name="ncbi_pdid" content="book-part">
|
|
<meta name="ncbi_acc" content="NBK599549">
|
|
<meta name="ncbi_domain" content="statpearls">
|
|
<meta name="ncbi_report" content="reader">
|
|
<meta name="ncbi_type" content="fulltext">
|
|
<meta name="ncbi_objectid" content="">
|
|
<meta name="ncbi_pcid" content="/NBK599549/?report=reader">
|
|
<meta name="ncbi_pagename" content="HIV-Related Endocrinopathies - StatPearls - NCBI Bookshelf">
|
|
<meta name="ncbi_bookparttype" content="chapter">
|
|
<meta name="ncbi_app" content="bookshelf">
|
|
<!-- Logger end -->
|
|
|
|
<!--component id="Page" label="meta"/-->
|
|
<script type="text/javascript" src="/corehtml/pmc/jatsreader/ptpmc_3.22/js/jr.boots.min.js"> </script><title>HIV-Related Endocrinopathies - StatPearls - NCBI Bookshelf</title>
|
|
<meta charset="utf-8">
|
|
<meta name="apple-mobile-web-app-capable" content="no">
|
|
<meta name="viewport" content="initial-scale=1,minimum-scale=1,maximum-scale=1,user-scalable=no">
|
|
<meta name="jr-col-layout" content="auto">
|
|
<meta name="robots" content="INDEX,FOLLOW,NOARCHIVE">
|
|
<meta name="citation_inbook_title" content="StatPearls [Internet]">
|
|
<meta name="citation_title" content="HIV-Related Endocrinopathies">
|
|
<meta name="citation_publisher" content="StatPearls Publishing">
|
|
<meta name="citation_date" content="2024/01/11">
|
|
<meta name="citation_author" content="Sri Ram Teja T. Sathi">
|
|
<meta name="citation_author" content="Catherine Anastasopoulou">
|
|
<meta name="citation_pmid" content="38261692">
|
|
<meta name="citation_fulltext_html_url" content="https://www.ncbi.nlm.nih.gov/books/NBK599549/">
|
|
<link rel="schema.DC" href="http://purl.org/DC/elements/1.0/">
|
|
<meta name="DC.Title" content="HIV-Related Endocrinopathies">
|
|
<meta name="DC.Type" content="Text">
|
|
<meta name="DC.Publisher" content="StatPearls Publishing">
|
|
<meta name="DC.Contributor" content="Sri Ram Teja T. Sathi">
|
|
<meta name="DC.Contributor" content="Catherine Anastasopoulou">
|
|
<meta name="DC.Date" content="2024/01/11">
|
|
<meta name="DC.Identifier" content="https://www.ncbi.nlm.nih.gov/books/NBK599549/">
|
|
<meta name="description" content="An estimated 37.9 million people were living with HIV at the end of 2018, of which 24.7 million could access anti-retroviral therapy (ART). While HIV was once considered a dreadful infection, the introduction of effective ART has transformed HIV into a chronic disease. Reducing HIV-related mortality with ART has meant an increased incidence of common health issues and conditions associated with aging, many of which have an endocrine basis. Individuals infected with HIV exhibit endocrine system dysfunction, ranging from subtle alterations in laboratory values without symptoms to overt glandular failure. Virtually every endocrine organ system can be involved. Although many of these changes can be seen with any significant systemic disease, some changes appear specific to HIV infection.">
|
|
<meta name="og:title" content="HIV-Related Endocrinopathies">
|
|
<meta name="og:type" content="book">
|
|
<meta name="og:description" content="An estimated 37.9 million people were living with HIV at the end of 2018, of which 24.7 million could access anti-retroviral therapy (ART). While HIV was once considered a dreadful infection, the introduction of effective ART has transformed HIV into a chronic disease. Reducing HIV-related mortality with ART has meant an increased incidence of common health issues and conditions associated with aging, many of which have an endocrine basis. Individuals infected with HIV exhibit endocrine system dysfunction, ranging from subtle alterations in laboratory values without symptoms to overt glandular failure. Virtually every endocrine organ system can be involved. Although many of these changes can be seen with any significant systemic disease, some changes appear specific to HIV infection.">
|
|
<meta name="og:url" content="https://www.ncbi.nlm.nih.gov/books/NBK599549/">
|
|
<meta name="og:site_name" content="NCBI Bookshelf">
|
|
<meta name="og:image" content="https://www.ncbi.nlm.nih.gov/corehtml/pmc/pmcgifs/bookshelf/thumbs/th-statpearls-lrg.png">
|
|
<meta name="twitter:card" content="summary">
|
|
<meta name="twitter:site" content="@ncbibooks">
|
|
<meta name="bk-non-canon-loc" content="/books/n/statpearls/article-149535/?report=reader">
|
|
<link rel="canonical" href="https://www.ncbi.nlm.nih.gov/books/NBK599549/">
|
|
<link href="https://fonts.googleapis.com/css?family=Archivo+Narrow:400,700,400italic,700italic&subset=latin" rel="stylesheet" type="text/css">
|
|
<link rel="stylesheet" href="/corehtml/pmc/jatsreader/ptpmc_3.22/css/libs.min.css">
|
|
<link rel="stylesheet" href="/corehtml/pmc/jatsreader/ptpmc_3.22/css/jr.min.css">
|
|
<meta name="format-detection" content="telephone=no">
|
|
<link rel="stylesheet" href="/corehtml/pmc/css/bookshelf/2.26/css/books.min.css" type="text/css">
|
|
<link rel="stylesheet" href="/corehtml/pmc/css/bookshelf/2.26/css//books_print.min.css" type="text/css" media="print">
|
|
<link rel="stylesheet" href="/corehtml/pmc/css/bookshelf/2.26/css/books_reader.min.css" type="text/css">
|
|
<style type="text/css">p a.figpopup{display:inline !important} .bk_tt {font-family: monospace} .first-line-outdent .bk_ref {display: inline} .body-content h2, .body-content .h2 {border-bottom: 1px solid #97B0C8} .body-content h2.inline {border-bottom: none} a.page-toc-label , .jig-ncbismoothscroll a {text-decoration:none;border:0 !important} .temp-labeled-list .graphic {display:inline-block !important} .temp-labeled-list img{width:100%}</style>
|
|
|
|
<link rel="shortcut icon" href="//www.ncbi.nlm.nih.gov/favicon.ico">
|
|
<meta name="ncbi_phid" content="CE8C4CC87C9163D10000000000BA009A.m_5">
|
|
<meta name='referrer' content='origin-when-cross-origin'/><link type="text/css" rel="stylesheet" href="//static.pubmed.gov/portal/portal3rc.fcgi/4216699/css/3852956/3849091.css"></head>
|
|
<body>
|
|
<!-- Book content! -->
|
|
|
|
|
|
<div id="jr" data-jr-path="/corehtml/pmc/jatsreader/ptpmc_3.22/"><div class="jr-unsupported"><table class="modal"><tr><td><span class="attn inline-block"></span><br />Your browser does not support the NLM PubReader view.<br />Go to <a href="/pmc/about/pr-browsers/">this page</a> to see a list of supported browsers<br />or return to the <br /><a href="/books/NBK599549/?report=classic">regular view</a>.</td></tr></table></div><div id="jr-ui" class="hidden"><nav id="jr-head"><div class="flexh tb"><div id="jr-tb1"><a id="jr-links-sw" class="hidden" title="Links"><svg xmlns="http://www.w3.org/2000/svg" version="1.1" x="0px" y="0px" viewBox="0 0 70.6 85.3" style="enable-background:new 0 0 70.6 85.3;vertical-align:middle" xml:space="preserve" width="24" height="24">
|
|
<style type="text/css">.st0{fill:#939598;}</style>
|
|
<g>
|
|
<path class="st0" d="M36,0C12.8,2.2-22.4,14.6,19.6,32.5C40.7,41.4-30.6,14,35.9,9.8"></path>
|
|
<path class="st0" d="M34.5,85.3c23.2-2.2,58.4-14.6,16.4-32.5c-21.1-8.9,50.2,18.5-16.3,22.7"></path>
|
|
<path class="st0" d="M34.7,37.1c66.5-4.2-4.8-31.6,16.3-22.7c42.1,17.9,6.9,30.3-16.4,32.5h1.7c-66.2,4.4,4.8,31.6-16.3,22.7 c-42.1-17.9-6.9-30.3,16.4-32.5"></path>
|
|
</g>
|
|
</svg> Books</a></div><div class="jr-rhead f1 flexh"><div class="head"></div><div class="body"><div class="t">HIV-Related Endocrinopathies</div><div class="j">StatPearls [Internet]</div></div><div class="tail"></div></div><div id="jr-tb2"><a id="jr-bkhelp-sw" class="btn wsprkl hidden" title="Help with NLM PubReader">?</a><a id="jr-help-sw" class="btn wsprkl hidden" title="Settings and typography in NLM PubReader"><svg xmlns="http://www.w3.org/2000/svg" viewBox="0 0 512 512" preserveAspectRatio="none"><path d="M462,283.742v-55.485l-29.981-10.662c-11.431-4.065-20.628-12.794-25.274-24.001 c-0.002-0.004-0.004-0.009-0.006-0.013c-4.659-11.235-4.333-23.918,0.889-34.903l13.653-28.724l-39.234-39.234l-28.72,13.652 c-10.979,5.219-23.68,5.546-34.908,0.889c-0.005-0.002-0.01-0.003-0.014-0.005c-11.215-4.65-19.933-13.834-24-25.273L283.741,50 h-55.484l-10.662,29.981c-4.065,11.431-12.794,20.627-24.001,25.274c-0.005,0.002-0.009,0.004-0.014,0.005 c-11.235,4.66-23.919,4.333-34.905-0.889l-28.723-13.653l-39.234,39.234l13.653,28.721c5.219,10.979,5.545,23.681,0.889,34.91 c-0.002,0.004-0.004,0.009-0.006,0.013c-4.649,11.214-13.834,19.931-25.271,23.998L50,228.257v55.485l29.98,10.661 c11.431,4.065,20.627,12.794,25.274,24c0.002,0.005,0.003,0.01,0.005,0.014c4.66,11.236,4.334,23.921-0.888,34.906l-13.654,28.723 l39.234,39.234l28.721-13.652c10.979-5.219,23.681-5.546,34.909-0.889c0.005,0.002,0.01,0.004,0.014,0.006 c11.214,4.649,19.93,13.833,23.998,25.271L228.257,462h55.484l10.595-29.79c4.103-11.538,12.908-20.824,24.216-25.525 c0.005-0.002,0.009-0.004,0.014-0.006c11.127-4.628,23.694-4.311,34.578,0.863l28.902,13.738l39.234-39.234l-13.66-28.737 c-5.214-10.969-5.539-23.659-0.886-34.877c0.002-0.005,0.004-0.009,0.006-0.014c4.654-11.225,13.848-19.949,25.297-24.021 L462,283.742z M256,331.546c-41.724,0-75.548-33.823-75.548-75.546s33.824-75.547,75.548-75.547 c41.723,0,75.546,33.824,75.546,75.547S297.723,331.546,256,331.546z"></path></svg></a><a id="jr-fip-sw" class="btn wsprkl hidden" title="Find"><svg xmlns="http://www.w3.org/2000/svg" viewBox="0 0 550 600" preserveAspectRatio="none"><path fill="none" stroke="#000" stroke-width="36" stroke-linecap="round" style="fill:#FFF" d="m320,350a153,153 0 1,0-2,2l170,170m-91-117 110,110-26,26-110-110"></path></svg></a><a id="jr-cmap-sw" class="btn wsprkl hidden" title="Table of Contents"><svg xmlns="http://www.w3.org/2000/svg" viewBox="0 0 100 100" preserveAspectRatio="none"><path d="M20,20h10v8H20V20zM36,20h44v8H36V20zM20,37.33h10v8H20V37.33zM36,37.33h44v8H36V37.33zM20,54.66h10v8H20V54.66zM36,54.66h44v8H36V54.66zM20,72h10v8 H20V72zM36,72h44v8H36V72z"></path></svg></a></div></div></nav><nav id="jr-dash" class="noselect"><nav id="jr-dash" class="noselect"><div id="jr-pi" class="hidden"><a id="jr-pi-prev" class="hidden" title="Previous page"><svg xmlns="http://www.w3.org/2000/svg" viewBox="0 0 100 100" preserveAspectRatio="none"><path d="M75,30 c-80,60 -80,0 0,60 c-30,-60 -30,0 0,-60"></path><text x="20" y="28" textLength="60" style="font-size:25px">Prev</text></svg></a><div class="pginfo">Page <i class="jr-pg-pn">0</i> of <i class="jr-pg-lp">0</i></div><a id="jr-pi-next" class="hidden" title="Next page"><svg xmlns="http://www.w3.org/2000/svg" viewBox="0 0 100 100" preserveAspectRatio="none"><path d="M25,30c80,60 80,0 0,60 c30,-60 30,0 0,-60"></path><text x="20" y="28" textLength="60" style="font-size:25px">Next</text></svg></a></div><div id="jr-is-tb"><a id="jr-is-sw" class="btn wsprkl hidden" title="Switch between Figures/Tables strip and Progress bar"><svg xmlns="http://www.w3.org/2000/svg" viewBox="0 0 100 100" preserveAspectRatio="none"><rect x="10" y="40" width="20" height="20"></rect><rect x="40" y="40" width="20" height="20"></rect><rect x="70" y="40" width="20" height="20"></rect></svg></a></div><nav id="jr-istrip" class="istrip hidden"><a id="jr-is-prev" href="#" class="hidden" title="Previous"><svg xmlns="http://www.w3.org/2000/svg" viewBox="0 0 100 100" preserveAspectRatio="none"><path d="M80,40 60,65 80,90 70,90 50,65 70,40z M50,40 30,65 50,90 40,90 20,65 40,40z"></path><text x="35" y="25" textLength="60" style="font-size:25px">Prev</text></svg></a><a id="jr-is-next" href="#" class="hidden" title="Next"><svg xmlns="http://www.w3.org/2000/svg" viewBox="0 0 100 100" preserveAspectRatio="none"><path d="M20,40 40,65 20,90 30,90 50,65 30,40z M50,40 70,65 50,90 60,90 80,65 60,40z"></path><text x="15" y="25" textLength="60" style="font-size:25px">Next</text></svg></a></nav><nav id="jr-progress"></nav></nav></nav><aside id="jr-links-p" class="hidden flexv"><div class="tb sk-htbar flexh"><div><a class="jr-p-close btn wsprkl">Done</a></div><div class="title-text f1">NCBI Bookshelf</div></div><div class="cnt lol f1"><a href="/books/">Home</a><a href="/books/browse/">Browse All Titles</a><a class="btn share" target="_blank" rel="noopener noreferrer" href="https://www.facebook.com/sharer/sharer.php?u=https://www.ncbi.nlm.nih.gov/books/NBK599549/"><svg xmlns="http://www.w3.org/2000/svg" viewBox="0 0 33 33" style="vertical-align:middle" width="24" height="24" preserveAspectRatio="none"><g><path d="M 17.996,32L 12,32 L 12,16 l-4,0 l0-5.514 l 4-0.002l-0.006-3.248C 11.993,2.737, 13.213,0, 18.512,0l 4.412,0 l0,5.515 l-2.757,0 c-2.063,0-2.163,0.77-2.163,2.209l-0.008,2.76l 4.959,0 l-0.585,5.514L 18,16L 17.996,32z"></path></g></svg> Share on Facebook</a><a class="btn share" target="_blank" rel="noopener noreferrer" href="https://twitter.com/intent/tweet?url=https://www.ncbi.nlm.nih.gov/books/NBK599549/&text=HIV-Related%20Endocrinopathies"><svg xmlns="http://www.w3.org/2000/svg" viewBox="0 0 33 33" style="vertical-align:middle" width="24" height="24"><g><path d="M 32,6.076c-1.177,0.522-2.443,0.875-3.771,1.034c 1.355-0.813, 2.396-2.099, 2.887-3.632 c-1.269,0.752-2.674,1.299-4.169,1.593c-1.198-1.276-2.904-2.073-4.792-2.073c-3.626,0-6.565,2.939-6.565,6.565 c0,0.515, 0.058,1.016, 0.17,1.496c-5.456-0.274-10.294-2.888-13.532-6.86c-0.565,0.97-0.889,2.097-0.889,3.301 c0,2.278, 1.159,4.287, 2.921,5.465c-1.076-0.034-2.088-0.329-2.974-0.821c-0.001,0.027-0.001,0.055-0.001,0.083 c0,3.181, 2.263,5.834, 5.266,6.438c-0.551,0.15-1.131,0.23-1.73,0.23c-0.423,0-0.834-0.041-1.235-0.118 c 0.836,2.608, 3.26,4.506, 6.133,4.559c-2.247,1.761-5.078,2.81-8.154,2.81c-0.53,0-1.052-0.031-1.566-0.092 c 2.905,1.863, 6.356,2.95, 10.064,2.95c 12.076,0, 18.679-10.004, 18.679-18.68c0-0.285-0.006-0.568-0.019-0.849 C 30.007,8.548, 31.12,7.392, 32,6.076z"></path></g></svg> Share on Twitter</a></div></aside><aside id="jr-cmap-p" class="hidden flexv"><div class="tb sk-htbar flexh"><div><a class="jr-p-close btn wsprkl">Done</a></div><div class="title-text f1">In Page Navigation</div></div><div class="cnt lol f1"><a href="/books/n/statpearls/?report=reader">Title Information</a><a href="/books/n/statpearls/toc/?report=reader">Table of Contents Page</a><a href="#_NBK599549_">HIV-Related Endocrinopathies</a></div></aside><aside id="jr-help-p" class="hidden flexv"><div class="tb sk-htbar flexh"><div><a class="jr-p-close btn wsprkl">Done</a></div><div class="title-text f1">Settings</div></div><div class="cnt f1"><div id="jr-typo-p" class="typo"><div><a class="sf btn wsprkl">A-</a><a class="lf btn wsprkl">A+</a></div><div><a class="bcol-auto btn wsprkl"><svg xmlns="http://www.w3.org/2000/svg" viewBox="0 0 200 100" preserveAspectRatio="none"><text x="10" y="70" style="font-size:60px;font-family: Trebuchet MS, ArialMT, Arial, sans-serif" textLength="180">AUTO</text></svg></a><a class="bcol-1 btn wsprkl"><svg xmlns="http://www.w3.org/2000/svg" viewBox="0 0 100 100" preserveAspectRatio="none"><path d="M15,25 85,25zM15,40 85,40zM15,55 85,55zM15,70 85,70z"></path></svg></a><a class="bcol-2 btn wsprkl"><svg xmlns="http://www.w3.org/2000/svg" viewBox="0 0 100 100" preserveAspectRatio="none"><path d="M5,25 45,25z M55,25 95,25zM5,40 45,40z M55,40 95,40zM5,55 45,55z M55,55 95,55zM5,70 45,70z M55,70 95,70z"></path></svg></a></div></div><div class="lol"><a class="" href="/books/NBK599549/?report=classic">Switch to classic view</a><a href="/books/NBK599549/?report=printable">Print View</a></div></div></aside><aside id="jr-bkhelp-p" class="hidden flexv"><div class="tb sk-htbar flexh"><div><a class="jr-p-close btn wsprkl">Done</a></div><div class="title-text f1">Help</div></div><div class="cnt f1 lol"><a id="jr-helpobj-sw" data-path="/corehtml/pmc/jatsreader/ptpmc_3.22/" data-href="/corehtml/pmc/jatsreader/ptpmc_3.22/img/bookshelf/help.xml" href="">Help</a><a href="mailto:info@ncbi.nlm.nih.gov?subject=PubReader%20feedback%20%2F%20NBK599549%20%2F%20sid%3ACE8B5AF87C7FFCB1_0191SID%20%2F%20phid%3ACE8C4CC87C9163D10000000000BA009A.4">Send us feedback</a><a id="jr-about-sw" data-path="/corehtml/pmc/jatsreader/ptpmc_3.22/" data-href="/corehtml/pmc/jatsreader/ptpmc_3.22/img/bookshelf/about.xml" href="">About PubReader</a></div></aside><aside id="jr-objectbox" class="thidden hidden"><div class="jr-objectbox-close wsprkl">✘</div><div class="jr-objectbox-inner cnt"><div class="jr-objectbox-drawer"></div></div></aside><nav id="jr-pm-left" class="hidden"><svg xmlns="http://www.w3.org/2000/svg" viewBox="0 0 40 800" preserveAspectRatio="none"><text font-stretch="ultra-condensed" x="800" y="-15" text-anchor="end" transform="rotate(90)" font-size="18" letter-spacing=".1em">Previous Page</text></svg></nav><nav id="jr-pm-right" class="hidden"><svg xmlns="http://www.w3.org/2000/svg" viewBox="0 0 40 800" preserveAspectRatio="none"><text font-stretch="ultra-condensed" x="800" y="-15" text-anchor="end" transform="rotate(90)" font-size="18" letter-spacing=".1em">Next Page</text></svg></nav><nav id="jr-fip" class="hidden"><nav id="jr-fip-term-p"><input type="search" placeholder="search this page" id="jr-fip-term" autocorrect="off" autocomplete="off" /><a id="jr-fip-mg" class="wsprkl btn" title="Find"><svg xmlns="http://www.w3.org/2000/svg" viewBox="0 0 550 600" preserveAspectRatio="none"><path fill="none" stroke="#000" stroke-width="36" stroke-linecap="round" style="fill:#FFF" d="m320,350a153,153 0 1,0-2,2l170,170m-91-117 110,110-26,26-110-110"></path></svg></a><a id="jr-fip-done" class="wsprkl btn" title="Dismiss find">✘</a></nav><nav id="jr-fip-info-p"><a id="jr-fip-prev" class="wsprkl btn" title="Jump to previuos match">◀</a><button id="jr-fip-matches">no matches yet</button><a id="jr-fip-next" class="wsprkl btn" title="Jump to next match">▶</a></nav></nav></div><div id="jr-epub-interstitial" class="hidden"></div><div id="jr-content"><article data-type="main"><div class="main-content lit-style" itemscope="itemscope" itemtype="http://schema.org/CreativeWork"><div class="meta-content fm-sec"><div class="fm-sec"><h1 id="_NBK599549_"><span class="title" itemprop="name">HIV-Related Endocrinopathies</span></h1><p class="contribs">Sathi SRTT, Anastasopoulou C.</p><p class="fm-aai"><a href="#_NBK599549_pubdet_">Publication Details</a></p></div></div><div class="jig-ncbiinpagenav body-content whole_rhythm" data-jigconfig="allHeadingLevels: ['h2'],smoothScroll: false" itemprop="text"><div id="article-149535.s1"><h2 id="_article-149535_s1_">Continuing Education Activity</h2><p>HIV infection can affect virtually every endocrine organ system in the body. Endocrine dysfunction secondary to neoplastic and opportunistic infectious involvement of endocrine organs was pervasive during the early AIDS pandemic. However, the current widespread use of effective antiretroviral therapy permits individuals with HIV a lifespan approaching that of the general population. Consequently, individuals with chronic HIV infection develop endocrinopathies commonly seen within the general population. Still, HIV status and antiretroviral therapy appear to be independent risk factors for developing many endocrinological disorders. Inadequately managed hormonal dysfunction can adversely affect quality of life and increase overall morbidity and mortality.</p><p>HIV status can present unique challenges in diagnosing and managing endocrinopathies. This activity reviews the epidemiology, etiology, presenting symptomatology, diagnostic evaluation, and management of endocrinopathies in individuals with HIV and highlights the role of the interprofessional team in improving outcomes for these patients.</p><p>
|
|
<b>Objectives:</b>
|
|
<ul><li class="half_rhythm"><div>Assess the risk of an individual with HIV developing various endocrinopathies.</div></li><li class="half_rhythm"><div>Compare and contrast the endocrinological adverse effects and drug interactions of medications commonly used in the management of HIV disease.</div></li><li class="half_rhythm"><div>Identify the unique challenges in diagnosing and managing endocrinopathies in individuals with HIV.</div></li><li class="half_rhythm"><div>Develop and implement effective interprofessional healthcare team strategies to improve outcomes for patients with HIV who develop an endocrinopathy.</div></li></ul>
|
|
<a href="https://www.statpearls.com/account/trialuserreg/?articleid=149535&utm_source=pubmed&utm_campaign=reviews&utm_content=149535" ref="pagearea=body&targetsite=external&targetcat=link&targettype=uri">Access free multiple choice questions on this topic.</a>
|
|
</p></div><div id="article-149535.s2"><h2 id="_article-149535_s2_">Introduction</h2><p>An estimated 37.9 million people were living with HIV at the end of 2018, of which 24.7 million could access anti-retroviral therapy (ART). While HIV was once considered a dreadful infection, the introduction of effective ART has transformed HIV into a chronic disease. Reducing HIV-related mortality with ART has meant an increased incidence of common health issues and conditions associated with aging, many of which have an endocrine basis. Individuals infected with HIV exhibit endocrine system dysfunction, ranging from subtle alterations in laboratory values without symptoms to overt glandular failure. Virtually every endocrine organ system can be involved. Although many of these changes can be seen with any significant systemic disease, some changes appear specific to HIV infection.</p><p>During the early AIDS pandemic, endocrinopathic manifestations of HIV infection were mostly secondary to opportunistic infections and HIV-related neoplasms directly involving endocrine organs. However, with the widespread use of ART and the associated reduction in the incidence of the late manifestations of AIDS, much attention has been paid to endocrine dysfunction due to the direct effects of HIV infection, immune reconstitution, and the use of ART.<a class="bibr" href="#article-149535.r1" rid="article-149535.r1">[1]</a><a class="bibr" href="#article-149535.r2" rid="article-149535.r2">[2]</a></p></div><div id="article-149535.s3"><h2 id="_article-149535_s3_">Etiology</h2><p>
|
|
<b>Thyroid Dysfunction</b>
|
|
</p><p>Similar to euthyroid sick syndrome, which is considered an adaptive response to any significant illness, advanced HIV disease can be associated with low tetraiodothyronine (T<sub>4</sub>) and triiodothyronine (T<sub>3</sub>) levels. However, the elevated reverse T<sub>3 </sub>(rT<sub>3</sub>) levels characteristic of euthyroid sick syndrome may not be seen in advanced HIV disease.</p><p>Neoplasms and opportunistic pathogens can invade endocrine organs and cause dysfunction.<a class="bibr" href="#article-149535.r3" rid="article-149535.r3">[3]</a><b> </b>Kaposi sarcoma and lymphoma can infiltrate the thyroid gland, causing enlargement or destruction and hypothyroidism.<b> </b><i>Pneumocystis jiroveci</i> and <i>Cryptococcus neoformans</i> can invade the thyroid gland and cause inflammatory thyroiditis, resulting in either hypo- or hyperthyroidism. </p><p>Medications used as a part of ART or when treating opportunistic infections, such as rifampin, phenytoin, ketoconazole, and ritonavir, can alter the clearance of thyroid hormones through the induction of hepatic microsomal enzymes.<a class="bibr" href="#article-149535.r4" rid="article-149535.r4">[4]</a> Interferon-α, used to treat Kaposi sarcoma, has been associated with the development of autoimmune thyroiditis resulting in hypo- or hyperthyroidism. Immune reconstitution, a phenomenon of exaggerated immune response after the reversal of lymphopenia occurring after ART initiation, can induce various autoimmune diseases, including Graves disease.<a class="bibr" href="#article-149535.r5" rid="article-149535.r5">[5]</a><a class="bibr" href="#article-149535.r6" rid="article-149535.r6">[6]</a><b> </b></p><p>
|
|
<b>Adrenal Dysfunction</b>
|
|
</p><p>HIV can cause adrenal insufficiency via direct involvement of the gland or the formation of anti-adrenal antibodies secondary to polyclonal B-lymphocyte activation. Individuals with HIV may also have elevated basal cortisol levels with normal or elevated adrenocorticotrophic hormone (ACTH) levels; this has been attributed to the stimulation of cortisol secretion by Interleukin 1 and tumor necrosis factor (TNF) and the stimulation of ACTH and corticotropin-releasing hormone (CRH) by Interleukins 1 and 6.<a class="bibr" href="#article-149535.r7" rid="article-149535.r7">[7]</a> The HIV envelope protein gp120 also increases cortisol. Interleukins 2 and 4 (IL-2, IL-4) and HIV-1 viral protein R (Vpr) increase sensitivity to cortisol.<a class="bibr" href="#article-149535.r8" rid="article-149535.r8">[8]</a><a class="bibr" href="#article-149535.r9" rid="article-149535.r9">[9]</a> It is unclear if this pattern of hypercortisolemia is a favorable adaptive response with anti-inflammatory properties or a harmful effect secondary to further immunosuppression.</p><p>A syndrome of glucocorticoid resistance has been described in patients with HIV, characterized by elevated cortisol and normal or high ACTH levels with weakness, weight loss, and hyperpigmentation. This syndrome has been attributed to decreased receptor affinity for glucocorticoids. Individuals with HIV may have lower basal adrenal androgen levels and an elevated cortisol to dehydroepiandrosterone-sulfate (DHEA-S) ratio. DHEA-S levels decline as HIV progresses.<a class="bibr" href="#article-149535.r10" rid="article-149535.r10">[10]</a></p><p>Adrenal gland involvement by opportunistic infections was common in the pre-ART era; more than 90% of untreated patients with HIV in an autopsy series were found to have cytomegalovirus-induced adrenalitis. Other organisms implicated in adrenal dysfunction include <i>C neoformans</i>, <i>Mycobacterium avium-intracellulare</i>, <i>Mycobacterium tuberculosis</i>, <i>P jiroveci</i>, <i>Histoplasma capsulatum</i>, and <i>Toxoplasma gondii</i>. Kaposi sarcoma and lymphoma can also infiltrate the adrenal gland directly.<a class="bibr" href="#article-149535.r11" rid="article-149535.r11">[11]</a></p><p>The antifungal ketoconazole reduces cortisol synthesis; phenytoin and rifampin accelerate steroid clearance. Megestrol acetate, used for HIV-related anorexia and muscle wasting, has intrinsic cortisol-like activity and can suppress the hypothalamic-pituitary-adrenal axis. The long-term use of megestrol can cause Cushing syndrome; its abrupt discontinuation can precipitate adrenal insufficiency. Some protease inhibitors reduce the metabolism of injected triamcinolone and inhaled glucocorticoids, like fluticasone and budesonide, leading to Cushing syndrome or adrenal insufficiency in the case of sudden medication discontinuation.<a class="bibr" href="#article-149535.r12" rid="article-149535.r12">[12]</a>  </p><p>
|
|
<b>Bone Disorders and Osteoporosis</b>
|
|
</p><p>Individuals with HIV may develop osteoporosis from chronic inflammation. HIV glycoprotein GP120 induces T cells to produce a receptor-activator of nuclear factor-kappaB ligand (RANK-L); RANK-L activates osteoclasts and promotes bone resorption. The elevated levels of TNF-α and IL-1 seen in HIV infection also activate RANK-L.<a class="bibr" href="#article-149535.r13" rid="article-149535.r13">[13]</a><b> </b>Additionally, patients infected with HIV frequently have a higher prevalence of the traditional risk factors for osteoporosis, including lower body weight, poor nutrition, tobacco and alcohol use, hypogonadism, and early menopause. Patients with HIV who are coinfected with hepatitis B or C have an increased fracture risk compared to patients infected only with HIV.</p><p>Patients with HIV being treated with ART have an increased prevalence of reduced bone mineral density and osteoporosis than either matched controls or untreated HIV patients.<a class="bibr" href="#article-149535.r13" rid="article-149535.r13">[13]</a> The rate of bone loss is the highest during the first 1 to 2 years after ART initiation and approaches the degree observed in patients using aromatase inhibitors or glucocorticoids. This rapid decrease in bone density has been attributed to immune reconstitution with the resultant upregulation of RANK-L–mediated bone resorption. Tenofovir disoproxil fumarate is associated with a more significant loss of bone density in individuals with HIV; bone density improves with switching to a non–tenofovir-based regimen. This decrease in bone density has also been observed in HIV-negative patients who take tenofovir disoproxil fumarate for prophylaxis.<a class="bibr" href="#article-149535.r14" rid="article-149535.r14">[14]</a></p><p>Efavirenz has been associated with decreased serum vitamin D levels via its effects on vitamin D metabolism and binding protein. However, with long-term ART and viral suppression, bone density may increase and stabilize.<a class="bibr" href="#article-149535.r15" rid="article-149535.r15">[15]</a> </p><p>Tenofovir disoproxil fumarate and cidofovir, an antiviral used to treat cytomegalovirus (CMV), can cause proximal renal tubulopathy with resulting hypocalcemia and hypophosphatemia. Foscarnet, another antiviral used to treat CMV, can cause hypocalcemia by complexing with ionized calcium; it may also cause hypomagnesemia and hypokalemia through its effects on renal tubular absorption.<a class="bibr" href="#article-149535.r16" rid="article-149535.r16">[16]</a> The combination of foscarnet and pentamidine, a medication used to prevent and treat <i>P jiroveci</i> pneumonia, can cause severe hypocalcemia.<a class="bibr" href="#article-149535.r17" rid="article-149535.r17">[17]</a></p><p>AIDS-related lymphoma and mycobacterial or <i>C neoformans </i>infections can cause hypercalcemia due to increased extrarenal activation of vitamin D by activated macrophages or tumor cells. Occasionally, hypercalcemia may occur after initiating ART as part of an immune reconstitution syndrome.<a class="bibr" href="#article-149535.r18" rid="article-149535.r18">[18]</a></p><p>
|
|
<b>Gonadal Dysfunction in Men</b>
|
|
</p><p>Low testosterone levels are frequently observed in men with HIV. Secondary hypogonadism, or hypogonadotropic hypogonadism, characterized by low testosterone levels and inappropriately normal or low gonadotropin levels, is the most commonly observed type of gonadal dysfunction in individuals with HIV.<a class="bibr" href="#article-149535.r19" rid="article-149535.r19">[19]</a> The etiology of this secondary hypogonadism is likely multifactorial. Chronic illness and weight loss, both observed in advanced HIV disease, are known causes of hypogonadotropic hypogonadism through alteration of the hypothalamic-pituitary axis. The increased levels of IL-1 and TNF-α in HIV suppress the hypothalamic-pituitary axis and decrease testicular steroidogenesis. Direct invasion of the hypothalamus-pituitary unit by opportunistic central nervous system infections like <i>T gondii</i>, CMV, and C<i>andida</i> spp can also occur in untreated advanced HIV. </p><p>Individuals with HIV are at an increased risk for malignancies requiring chemoradiation that can damage testicular cells and cause primary hypogonadism. Primary hypogonadism, or hypergonadotropic hypogonadism, is characterized by low testosterone and elevated gonadotropin levels. Opportunistic infection of the testes by <i>Mycobacteria </i>spp, <i>Treponema pallidum</i>, and fungi can also occur in advanced untreated HIV. </p><p>Various medications used to treat opportunistic infections can impair testosterone levels. Ketoconazole inhibits gonadal steroidogeneis. Glucocorticoids, megestrol acetate, and methadone can suppress the hypothalamic-pituitary-gonadal axis. Psychotropic medication-induced hyperprolactinemia may also reduce gonadotropin levels.<a class="bibr" href="#article-149535.r20" rid="article-149535.r20">[20]</a></p><p>
|
|
<b>Gonadal Dysfunction in Women</b>
|
|
</p><p>Women with HIV are at an increased risk for anovulatory cycles and secondary amenorrhea due to disruption in the hypothalamic-pituitary-gonadal axis via mechanisms similar to those inducing secondary hypogonadism in men. Women with HIV also have lower levels of estradiol, testosterone, and DHEA-S than women without HIV.</p><p>Data regarding the influence of HIV on the onset of menopause is mixed. Many studies that showed an earlier onset of menopause in HIV-infected women relied on self-reported amenorrhea for more than 12 months to define menopause. However, prolonged secondary amenorrhea is common in HIV-infected women and can be falsely interpreted as menopause. Nevertheless, prolonged amenorrhea from anovulatory cycles or premature menopause may have similar health implications, such as effects on bone health and all-cause mortality.<a class="bibr" href="#article-149535.r21" rid="article-149535.r21">[21]</a><a class="bibr" href="#article-149535.r22" rid="article-149535.r22">[22]</a></p><p>Contraception in HIV has received much attention. There are mixed data regarding depot medroxyprogesterone acetate potentially increasing susceptibility to acquiring HIV infection secondary to its glucocorticoid mimetic effects and effects on the vaginal epithelial lining. There is also some concern that ART regimens containing ritonavir may decrease the effectiveness of combined oral contraceptives.<a class="bibr" href="#article-149535.r23" rid="article-149535.r23">[23]</a></p><p>
|
|
<b>Growth Hormone Deficiency</b>
|
|
</p><p>Before the advent of ART, individuals with advanced HIV- and AIDS-related wasting syndrome were found to have elevated growth hormone (GH) and low insulin-like growth factor-1 (IGF-1) levels, suggesting a condition of GH resistance. These changes were not observed in HIV-infected patients without wasting syndromes.<a class="bibr" href="#article-149535.r24" rid="article-149535.r24">[24]</a></p><p>HIV-related lipodystrophy became a commonly observed metabolic abnormality after the introduction of ART. GH axis dysfunction was investigated as a possible cause of lipodystrophy due to the known role of GH in promoting lipolysis, including that of visceral fat. Multiple studies using provocative testing with various cutoffs for GH levels showed a higher prevalence of biochemical GH deficiency in individuals with HIV than in controls; the clinical significance of this is unclear. Basal GH levels and the amplitude of GH pulses were lower in individuals with HIV with lipodystrophy than in individuals with HIV but no lipodystrophy and individuals without HIV. However, GH pulse frequency was similar in all groups. Several mechanistic causes of these findings have been suggested.<a class="bibr" href="#article-149535.r25" rid="article-149535.r25">[25]</a></p><p>The percent increase in GH levels during provocative testing with GH-releasing hormone and arginine (GHRH+ARG) is much higher than with GH alone in individuals with HIV lipodystrophy when compared to those without lipodystrophy and healthy controls; arginine was a more potent stimulator of GH release in individuals with HIV lipodystrophy. Arginine provokes GH secretion via inhibition of somatostatin tone, and these results suggest that individuals with HIV lipodystrophy have a higher baseline somatostatin tone as the cause of reduced GH secretion.<a class="bibr" href="#article-149535.r25" rid="article-149535.r25">[25]</a></p><p>Free fatty acids (FFA) are known inhibitors of GH secretion. Individuals with HIV lipodystrophy have higher baseline FFA levels. Administering acipimox reduces circulating FFA and has more effectively increased GH levels during provocative testing of individuals with HIV lipodystrophy than in healthy controls. The natural GH secretagogue ghrelin is lower in individuals with HIV lipodystrophy than in healthy controls. ART may indirectly contribute to biochemical GH deficiency by promoting visceral obesity, but as GH deficiency and visceral obesity promote each other, it is difficult to establish cause and effect. However, GH deficiency in individuals with HIV is not entirely explained by visceral obesity; the GH peak after GHRH+ARG stimulation was lower in patients with HIV than in HIV-negative patients with obesity of predominantly visceral fat. HIV positivity, with its associated chronic inflammatory state, premature aging, fat redistribution, and general health status, may all contribute to GH deficiency.<a class="bibr" href="#article-149535.r24" rid="article-149535.r24">[24]</a><a class="bibr" href="#article-149535.r26" rid="article-149535.r26">[26]</a></p><p>
|
|
<b>Metabolic Dysfunction</b>
|
|
</p><p>
|
|
<b>HIV- and AIDS-Wasting Syndromes</b>
|
|
</p><p>"Wasting" is the involuntary loss of body weight and cellular mass. Weight loss or wasting was one of the most common AIDS-defining conditions before the introduction of ART. In addition to fat loss, wasting is characterized by a loss of predominately muscle mass and is directly associated with increased mortality and morbidity. Various definitions for these wasting syndromes include a greater than 10% loss in body weight since the initial clinical visit, a decrease in body mass index (BMI) to <20 kg/m<sup>2</sup> since the most recent prior visit, or a greater than 5% loss in total body weight in 6 months, with the loss sustained for more than 1 year.<a class="bibr" href="#article-149535.r27" rid="article-149535.r27">[27]</a></p><p>The etiology of AIDS-wasting syndrome is likely multifactorial and includes various adverse psychosocial and financial factors in addition to pathophysiologic ones. Patients with AIDS may have oropharyngoesophageal dysphagia and odynophagia secondary to opportunistic infection with CMV, herpetic infection, and <i>Candida </i>spp. Secondary opportunistic infections of the gastrointestinal tract may also result in malabsorption of nutrients.</p><p>Normal GH levels are essential for maintaining protein balance and muscle mass. Patients with HIV- and AIDS-wasting syndromes routinely have elevated GH and low IGF-1 levels suggestive of GH resistance. Testosterone levels also correlate closely with lean muscle mass. Before the ART era, hypogonadism was the most frequently reported endocrinopathy in men with HIV. Greater than 67% of men with untreated HIV had symptoms suggestive of hypogonadism, and greater than 50% had low testosterone levels. Women with AIDS also have lower testosterone levels.<a class="bibr" href="#article-149535.r28" rid="article-149535.r28">[28]</a></p><p>Additionally, patients with HIV are in a hypermetabolic state with an elevated resting energy expenditure mediated by IL-1, TNF, and interferon-α. The introduction of ART has not led to a consistent reversal or reduction in the prevalence of HIV-associated weight loss.<a class="bibr" href="#article-149535.r29" rid="article-149535.r29">[29]</a><a class="bibr" href="#article-149535.r30" rid="article-149535.r30">[30]</a><a class="bibr" href="#article-149535.r31" rid="article-149535.r31">[31]</a>  </p><p>
|
|
<b>Disorders of Fat Distribution, Glucose, and Lipid Metabolism</b>
|
|
</p><p>Before the introduction of ART, a wasting syndrome characterized by the loss of body muscle and fat and low cholesterol levels was the most commonly described metabolic abnormality in individuals with HIV. However, after the introduction and widespread use of ART, various abnormalities in body fat composition, glucose tolerance, and lipid metabolism were described. Initially, these clinical findings were grouped into a single syndrome similar to the metabolic syndrome called HIV lipodystrophy. HIV lipodystrophy was thought to be related to ART, particularly protease inhibitors. However, it soon became apparent that these metabolic abnormalities have a multifactorial origin and vary among patients.</p><p>
|
|
<b>Lipoatrophy and Lipohypertrophy</b>
|
|
</p><p>Lipoatrophy is characterized by the diffuse loss of subcutaneous fat in the legs, buttocks, arms, and face; the lower body and face are commonly more severely affected. Lipoatrophy is distinct from HIV-wasting syndrome. Exposure to nucleoside reverse transcriptase inhibitors (NRTIs), like stavudine and zidovudine, is the most significant risk factor for developing lipoatrophy; the risk is lower with other NTIs, like abacavir and tenofovir.<a class="bibr" href="#article-149535.r32" rid="article-149535.r32">[32]</a><a class="bibr" href="#article-149535.r33" rid="article-149535.r33">[33]</a><a class="bibr" href="#article-149535.r34" rid="article-149535.r34">[34]</a> The pathophysiologic mechanism of NRTI-induced lipoatrophy is hypothesized to be underlying mitochondrial damage; NRTIs have a high affinity for the human mitochondrial DNA polymerase-γ. Protease inhibitors (PIs) are not felt to cause lipoatrophy when used in isolation but may act synergistically when paired with NRTIs.<a class="bibr" href="#article-149535.r35" rid="article-149535.r35">[35]</a> Integrase inhibitors do not likely contribute to lipoatrophy.<a class="bibr" href="#article-149535.r36" rid="article-149535.r36">[36]</a><a class="bibr" href="#article-149535.r37" rid="article-149535.r37">[37]</a> Other factors predisposing to the development of lipoatrophy include advanced HIV disease, low CD4 lymphocyte counts, male sex, and older age at ART initiation.</p><p>The etiology and risk factors for lipohypertrophy, or excess fat accumulation, are less understood. Excessive fat accumulation in the abdomen, dorsocervical area, neck, and breasts has been widely described since the advent of ART. Initially, PIs were thought to be primarily responsible for these clinical abnormalities. However, abnormal fat accumulation can develop in individuals never treated with PIs, and the risk does not appear elevated compared to other ART classes.<a class="bibr" href="#article-149535.r38" rid="article-149535.r38">[38]</a> Host and disease factors such as increased age, higher baseline fat content, and low CD4 lymphocyte counts at ART initiation may increase the risk for fat accumulation.<a class="bibr" href="#article-149535.r39" rid="article-149535.r39">[39]</a></p><p>
|
|
<b>Glucose Intolerance and Diabetes Mellitus</b>
|
|
</p><p>"Prediabetes" or "glucose intolerance" describes abnormal carbohydrate metabolism in patients who do not meet the current diagnostic criteria for diabetes mellitus. Multiple studies have described an increased incidence of insulin resistance and diabetes mellitus in individuals with HIV.<a class="bibr" href="#article-149535.r40" rid="article-149535.r40">[40]</a> Several factors likely contribute to the apparent increased risk of abnormal carbohydrate metabolism. Even in individuals with HIV, the dominant risk factors for developing diabetes mellitus are traditional factors such as increasing age, male sex, higher BMI, and non-White ethnicity. Improvement of HIV infection and restoration of health may be associated with weight gain, fat accumulation, and aging, all of which are associated with insulin resistance.<a class="bibr" href="#article-149535.r41" rid="article-149535.r41">[41]</a> </p><p>The lipoatrophy and lipohypertrophy seen in individuals with HIV are strongly associated with glucose intolerance, independent of total body weight. This may be due to decreased adiponectin levels increasing insulin resistance.<a class="bibr" href="#article-149535.r42" rid="article-149535.r42">[42]</a> However, several ART drug classes are also known to contribute to glucose intolerance.</p><p>PIs like ritonavir, lopinavir, and indinavir are known to increase insulin resistance via possible blockade of the glucose transporter type-4 (GLUT-4). NRTIs such as zidovudine and stavudine can increase insulin resistance by affecting body composition and mitochondrial function.<a class="bibr" href="#article-149535.r43" rid="article-149535.r43">[43]</a> Pentamidine can cause beta cell toxicity and acute hypoglycemia; individuals who develop hypoglycemia while taking pentamidine are at risk for developing diabetes mellitus in the long term.<a class="bibr" href="#article-149535.r44" rid="article-149535.r44">[44]</a> Coinfection with hepatitis C further increases the risk of developing diabetes mellitus. The chronic inflammatory state has been shown to increase the risk of diabetes mellitus in the general population, and HIV infection causes chronic inflammation that does not entirely abate even with effective ART.<a class="bibr" href="#article-149535.r45" rid="article-149535.r45">[45]</a> </p><p>
|
|
<b>Lipid Abnormalities</b>
|
|
</p><p>Various lipid abnormalities are observed in individuals with HIV due to the infection, the use of ART, and changes in body composition. Patients with untreated HIV have elevated triglycerides and decreased low-density lipoproteins (LDL) and high-density lipoproteins (HDL). The degree of hypertriglyceridemia directly correlates with HIV RNA levels and may be secondary to viral inhibition of cholesterol efflux from macrophages.<a class="bibr" href="#article-149535.r46" rid="article-149535.r46">[46]</a><a class="bibr" href="#article-149535.r47" rid="article-149535.r47">[47]</a> Lipoatrophy and lipohypertrophy are associated with an increase in triglycerides and a decrease in HDL.</p><p>Several antiviral medications also contribute to dyslipidemia; these effects are particular to certain pharmaceuticals and are not always class-specific.</p><ul><li class="half_rhythm"><div>Protease Inhibitors
|
|
<ul><li class="half_rhythm"><div>Ritonavir is associated with hypertriglyceridemia, which can be severe. Even low-dose ritonavir used as a "booster" with other protease inhibitors is associated with elevated LDL, total cholesterol, and triglycerides, albeit to a lower extent.<a class="bibr" href="#article-149535.r48" rid="article-149535.r48">[48]</a> Ritonavir-boosted darunavir or atazanavir have less effect on serum lipids than ritonavir-boosted lopinavir.<a class="bibr" href="#article-149535.r49" rid="article-149535.r49">[49]</a><a class="bibr" href="#article-149535.r50" rid="article-149535.r50">[50]</a> Switching to an atazanavir-containing regimen is associated with a decline in triglyceride and total cholesterol.<a class="bibr" href="#article-149535.r51" rid="article-149535.r51">[51]</a> </div></li></ul>
|
|
</div></li><li class="half_rhythm"><div>Non-nucleoside Reverse Transcriptase Inhibitors
|
|
<ul><li class="half_rhythm"><div>The non-nucleoside reverse transcriptase inhibitor (NNTRI) efavirenz is associated with increased triglycerides, total cholesterol, LDL, and HDL. Rilpivirine causes much lower increases in plasma lipids compared to efavirenz.<a class="bibr" href="#article-149535.r52" rid="article-149535.r52">[52]</a> Etravirine did not cause significant lipid abnormalities compared to placebo.<a class="bibr" href="#article-149535.r53" rid="article-149535.r53">[53]</a> </div></li></ul>
|
|
</div></li><li class="half_rhythm"><div>Nucleoside Reverse Transcriptase Inhibitors
|
|
<ul><li class="half_rhythm"><div>Tenofovir disoproxyl fumarate and emtricitabine are not associated with adverse lipid profiles and, when combined, may have a mild lipid-lowering effect.<a class="bibr" href="#article-149535.r54" rid="article-149535.r54">[54]</a> The newer formulation of tenofovir, tenofovir alafenamide, may cause an elevation in total cholesterol, LDL, and HDL not seen with the original formula.<a class="bibr" href="#article-149535.r55" rid="article-149535.r55">[55]</a></div></li></ul>
|
|
</div></li><li class="half_rhythm"><div>Integrase Inhibitors
|
|
<ul><li class="half_rhythm"><div>All agents in this class are associated with a favorable lipid profile. Switching to an integrase inhibitor-containing regimen may decrease the levels of atherogenic lipids.<a class="bibr" href="#article-149535.r56" rid="article-149535.r56">[56]</a></div></li></ul>
|
|
</div></li></ul></div><div id="article-149535.s4"><h2 id="_article-149535_s4_">Epidemiology</h2><p>
|
|
<b>Thyroid Dysfunction</b>
|
|
</p><p>The prevalence of overt thyroid dysfunction in patients with HIV is equivalent to that of the general population at 1% to 3%. However, subclinical thyroid dysfunction is significantly more common in patients with HIV, possibly as high as 12%. Subtle alterations in thyroid function tests can be seen in as many as 30% of individuals with HIV.<a class="bibr" href="#article-149535.r3" rid="article-149535.r3">[3]</a></p><p>
|
|
<b>Adrenal Dysfunction</b>
|
|
</p><p>Before the introduction of ART, the prevalence of adrenal insufficiency in individuals with HIV, mainly attributable to neoplasms and opportunistic infections, was estimated between 5% and 10%.<a class="bibr" href="#article-149535.r11" rid="article-149535.r11">[11]</a> Current estimates of adrenal dysfunction in patients with HIV are lower but are known to vary amongst different populations and geographic areas.</p><p>
|
|
<b>Bone Disorders and Osteoporosis</b>
|
|
</p><p>Patients with HIV have a 6.7-fold higher prevalence of decreased bone mineral density than the general population; the prevalence of frank osteoporosis is 3.7-fold higher.<a class="bibr" href="#article-149535.r13" rid="article-149535.r13">[13]</a> Patients on ART have a 2.5-fold higher prevalence than those who are treatment-naïve. Additionally, the risk of fragility fracture in patients with HIV is estimated to be 35% to 68% higher than that of the general population. This increased risk of fragility fracture is apparent almost 10 years earlier in individuals with HIV than in the general population.</p><p>
|
|
<b>Gonadal Dysfunction</b>
|
|
</p><p>Before the introduction of ART, hypogonadism was the most frequently reported endocrinopathy in men with HIV. At that time, more than 67% of men had symptoms suggestive of hypogonadism, with more than 50% having low testosterone levels associated with weight loss, wasting, and low CD4 lymphocyte counts. Since the introduction of ART, various studies have estimated the prevalence of gonadal dysfunction in men with HIV between 13% and 40%. This wide estimate may be because of variations in the timing of blood draws and the assays employed.<a class="bibr" href="#article-149535.r19" rid="article-149535.r19">[19]</a><a class="bibr" href="#article-149535.r20" rid="article-149535.r20">[20]</a><a class="bibr" href="#article-149535.r57" rid="article-149535.r57">[57]</a></p><p>Anovulation and amenorrhea can be seen in up to 50% of women with low CD4 lymphocyte counts.<a class="bibr" href="#article-149535.r58" rid="article-149535.r58">[58]</a> As many as 50% of women with AIDS-wasting syndrome have low androgen levels.<a class="bibr" href="#article-149535.r59" rid="article-149535.r59">[59]</a><b> </b></p><p>
|
|
<b>Growth Hormone Deficiency</b>
|
|
</p><p>Most studies evaluating GH deficiency in patients with HIV have employed provocative testing with GHRH alone or GHRH+ARG. The prevalence of biochemical GH deficiency in all HIV-infected patients was approximately 30% when a peak GH value cutoff of 7.5 to 9.0 μg/L was used. The prevalence of GH deficiency remained significantly elevated at 15% when a lower cutoff of 5 μg/L was used. Even with a cutoff of 4.2 μg/L, the standard for non-HIV-infected patients with obesity, the prevalence of GH deficiency remains elevated at 10%.<a class="bibr" href="#article-149535.r24" rid="article-149535.r24">[24]</a></p><p>
|
|
<b>Metabolic Dysfunction</b>
|
|
</p><p>
|
|
<b>HIV- and AIDS-Wasting Syndromes</b>
|
|
</p><p>Before the introduction of ART, approximately 30% of individuals with HIV were noted to have tissue wasting, and weight loss or wasting syndrome accounted for 18% of new diagnoses of AIDS. Studies evaluating weight loss and wasting performed after the introduction of ART have not consistently demonstrated the expected reversal or cessation of weight loss in individuals with HIV. A retrospective analysis of patients from 2012 to 2018 revealed the cumulative prevalence of weight loss at 17.9% in patients on ART and 19.1% in those not on ART.<a class="bibr" href="#article-149535.r29" rid="article-149535.r29">[29]</a><a class="bibr" href="#article-149535.r60" rid="article-149535.r60">[60]</a></p><p>
|
|
<b>Lipoatrophy and Lipohypertrophy</b>
|
|
</p><p>Estimates of the prevalence of fat distribution abnormalities in individuals with HIV vary widely from 10% to 80% across studies, likely secondary to the lack of consensus about the definition of this syndrome and the methodology used for diagnosis. In a study of 452 individuals with HIV, the baseline prevalence of lipoatrophy, lipohypertrophy, and mixed forms was 35%, 44%, and 14%, respectively. After one year, 22% had new lipoatrophy, and 16% with baseline lipoatrophy no longer met the diagnostic criteria. At that same time, 23% developed new lipohypertrophy, and 15% of those with baseline lipohypertrophy experienced resolution.<a class="bibr" href="#article-149535.r61" rid="article-149535.r61">[61]</a> </p><p>
|
|
<b>Glucose Intolerance and Diabetes Mellitus</b>
|
|
</p><p>The estimated prevalence of diabetes mellitus in individuals with HIV has varied widely, likely secondary to different baseline characteristics of the study cohorts and varying diagnostic criteria. A study of individuals with HIV in the United States between 2009 and 2010 revealed a diabetes mellitus prevalence of 10.3%, rising to 14.1% after adjustment for common confounders in the general population. In addition to age and obesity, the duration of HIV and mean CD4 lymphocyte count were also associated with diabetes mellitus.<a class="bibr" href="#article-149535.r40" rid="article-149535.r40">[40]</a><b> </b></p><p>
|
|
<b>Lipid Abnormalities</b>
|
|
</p><p>A study of patients aged greater than 70 years living with HIV found dyslipidemia in 54% and cardiovascular disease in 23% of the 159 studied participants.<a class="bibr" href="#article-149535.r62" rid="article-149535.r62">[62]</a> PIs have been associated with dyslipidemia in 28% to 80% of patients taking this medication.<a class="bibr" href="#article-149535.r20" rid="article-149535.r20">[20]</a></p></div><div id="article-149535.s5"><h2 id="_article-149535_s5_">History and Physical</h2><p>
|
|
<b>Thyroid Dysfunction</b>
|
|
</p><p>Thyroid dysfunction may be subclinical or overt; subclinical dysfunction is, by definition, asymptomatic. Overt thyroid dysfunction may be due to a hypo- or hyperthyroid state.</p><p>Patients with overt hypothyroidism may report dry skin, cold intolerance, constipation, and fatigue; the physical examination may reveal bradycardia, muscle weakness, or delayed reflexes.<a class="bibr" href="#article-149535.r63" rid="article-149535.r63">[63]</a> Conversely, patients with hyperthyroidism may report heat intolerance, anxiety, palpitations, hyperdefecation, or frank diarrhea; the physical examination may reveal tachycardia, warm or moist skin, hyperreflexia, tremors, or lid retraction.<a class="bibr" href="#article-149535.r64" rid="article-149535.r64">[64]</a> Muscle weakness, menstrual disturbances, and goiter may be seen in conjunction with any thyroid dysfunction. Graves disease may present with characteristic ophthalmopathy (see <b>Image.</b> Graves Orbitopathy.).<a class="bibr" href="#article-149535.r65" rid="article-149535.r65">[65]</a> Destructive or infiltrative processes of the thyroid may be associated with local symptoms of pain and mass effect.</p><p>
|
|
<b>Adrenal Dysfunction</b>
|
|
</p><p>Patients with chronic adrenal insufficiency present with unexplained fatigue, nausea, abdominal discomfort, anorexia, diffuse aches, weight loss, or amenorrhea. If the patient has primary adrenal insufficiency, the physical examination may reveal hyperpigmentation of the vermilion borders, buccal mucosa, or palmar creases; hyperpigmentation may present as increased skin freckling. Acute adrenal insufficiency or adrenal crisis is usually precipitated by physiologic stress or underlying systemic illness and typically presents with profound hypotension with or without shock, hypoglycemia, fever, confusion, or coma.<a class="bibr" href="#article-149535.r66" rid="article-149535.r66">[66]</a><a class="bibr" href="#article-149535.r67" rid="article-149535.r67">[67]</a></p><p>Patients with hypercortisolemia or Cushing syndrome may present with weight gain, hair loss, easy bruising, muscle weakness, lethargy, depression, or decreased libido. A physical examination may reveal plethoric facies, central obesity with thin extremities, a dorsocervical fat pad, purple abdominal striae, thin skin, or proximal muscle weakness.<a class="bibr" href="#article-149535.r68" rid="article-149535.r68">[68]</a></p><p>
|
|
<b>Bone Disorders and Osteoporosis</b>
|
|
</p><p>Decreased bone mineral density is typically asymptomatic. Patients with osteoporosis may also be asymptomatic until a fragility fracture occurs; fragility fractures occur in the setting of low-energy trauma, such as a fall from standing height or less. The hip and distal forearm are common sites of fragility fractures. Decreased height, stooped posture, or midline back pain may indicate a vertebral compression fracture. However, osteoporosis also increases the frequency of non-fragility fractures.<a class="bibr" href="#article-149535.r69" rid="article-149535.r69">[69]</a></p><p>
|
|
<b>Gonadal Dysfunction</b>
|
|
</p><p>Men with hypogonadism often report erectile dysfunction, weight loss, low energy levels, and decreased sexual desire; depression and cognitive dysfunction are less frequently endorsed.<a class="bibr" href="#article-149535.r70" rid="article-149535.r70">[70]</a> If the hypogonadism is secondary to the involvement of the hypothalamic-pituitary unit by infections or neoplasms, symptoms such as headaches and visual disturbances may be present. The physical examination may reveal reduced muscle mass and a change in consistency or a decrease in the size of the testes. Gynecomastia may be present. A neurological exam, including an assessment of visual fields, should be performed if a hypothalamic-pituitary lesion is suspected.</p><p>In addition to secondary amenorrhea, women with decreased androgen levels may also report weight loss, fatigue, low mood, and low libido. </p><p>Individuals of both sexes with hypogonadism can present with low-energy trauma fractures from early-onset osteoporosis. </p><p>
|
|
<b>Growth Hormone Deficiency</b>
|
|
</p><p>Children with GH deficiency can have poor growth velocity, delayed bone age, short stature, an increased weight-to-height ratio, and failure to thrive, especially in advanced HIV disease or AIDS. Adults with GH deficiency present with an increase in fat mass, particularly central adiposity, decreased lean muscle mass, reduced energy, and a diminished sense of well-being. The symptoms of GH deficiency are more severe if the onset of the disease occurs in childhood. The clinical manifestations of GH deficiency are nonspecific and may overlap considerably with those of HIV infection and generally poor health.<a class="bibr" href="#article-149535.r24" rid="article-149535.r24">[24]</a></p><p>
|
|
<b>Metabolic Dysfunction</b>
|
|
</p><p>
|
|
<b>HIV- and AIDS-Wasting Syndromes</b>
|
|
</p><p>Individuals with AIDS-wasting syndrome present with weight loss, muscle weakness, and frequently poor overall health. They may report decreased appetite, dysphagia, odynophagia, diarrhea, and a history of opportunistic infections. The physical examination may reveal signs of weight loss and cachexia, such as temporal wasting and decreased skin fold thickness. Oropharyngeal mucous membranes should be evaluated for lesions suggestive of opportunistic infections from herpes simplex virus or <i>Candida</i> spp. Individuals with wasting syndromes and concurrent hypogonadism may have diminished sexual desire and erectile dysfunction. A psychosocial assessment is indicated to identify additional barriers to adequate nutritional intake.<a class="bibr" href="#article-149535.r30" rid="article-149535.r30">[30]</a> </p><p>
|
|
<b>Lipoatrophy and Lipohypertrophy</b>
|
|
</p><p>Lipoatrophy is characterized by the loss of subcutaneous fat, preferentially in the face and extremities. Facial lipoatrophy results in the development of concave cheeks, periorbital hollowing, and visible facial musculature. Loss of subcutaneous fat in the extremities may make subcutaneous veins and musculature more prominent.</p><p>Lipohypertrophy may result in a dorsocervical fat pad, lipomas, the enlargement of supraclavicular fat pads and anterior neck fat, and bilateral gynecomastia. A marked increase in abdominal girth secondary to increased adiposity may occur; the waist-to-hip ratio will increase accordingly. HIV-associated lipohypertrophy is predominantly secondary to increased visceral fat rather than subcutaneous fat. The inability to pinch subcutaneous fat between the fingers in the setting of increasing abdominal girth suggests visceral fat accumulation.<a class="bibr" href="#article-149535.r32" rid="article-149535.r32">[32]</a></p><p>
|
|
<b>Glucose Intolerance and Diabetes Mellitus</b>
|
|
</p><p>Individuals with diabetes mellitus can be asymptomatic, with a diagnosis made only by laboratory testing. Hyperglycemia can cause polyuria, polydipsia, visual disturbances, and symptoms of sensory neuropathy like numbness and tingling. The physical examination may reveal obesity or signs of insulin resistance like acanthosis nigricans. Long-standing untreated diabetes can also cause a catabolic state with significant weight loss.  </p><p>
|
|
<b>Lipid Abnormalities</b>
|
|
</p><p>Mild to moderate elevations in lipids are usually not clinically evident and can only be detected with laboratory evaluations. Patients may have coexisting obesity, diabetes mellitus, and premature coronary artery disease. Severe hypertriglyceridemia may present with acute pancreatitis or xanthomas.<a class="bibr" href="#article-149535.r71" rid="article-149535.r71">[71]</a></p></div><div id="article-149535.s6"><h2 id="_article-149535_s6_">Evaluation</h2><p>
|
|
<b>Thyroid Dysfunction</b>
|
|
</p><p>The cornerstone of the evaluation of thyroid function is the measurement of serum thyroid stimulating hormone (TSH) and free or total T<sub>4</sub> and T<sub>3</sub>.<a class="bibr" href="#article-149535.r72" rid="article-149535.r72">[72]</a> Primary hypothyroidism is characterized by an elevated TSH and low T<sub>4</sub>, while primary hyperthyroidism is characterized by a low TSH and elevated T<sub>4</sub>, T<sub>3</sub>, or both. The TSH level is an unreliable diagnostic indicator in central or secondary hypothyroidism; this diagnosis can be made if the T<sub>4</sub> is low in the proper clinical context. Thyroxine-binding globulin (TBG) levels correlate inversely with CD4 lymphocyte counts; this must be considered when interpreting total T<sub>4</sub> and total T<sub>3</sub> levels. Elevated levels of thyroid autoantibodies support a diagnosis of autoimmune thyroiditis as the cause of thyroid dysfunction.</p><p>In a patient with the signs, symptoms, and laboratory results suggestive of hyperthyroidism but the absence of a clear diagnosis, radioactive iodine uptake testing may be beneficial; Graves disease is associated with increased uptake of iodine, and destructive or infiltrative thyroiditis reveals reduced or no uptake. </p><p>
|
|
<b>Adrenal Dysfunction</b>
|
|
</p><p>Diagnosing adrenal insufficiency in patients with HIV can be challenging; the presenting symptoms are frequently nonspecific and overlap those of HIV infection. Hyponatremia, hyperkalemia, and hypoglycemia are often seen in patients with adrenal insufficiency. Baseline cortisol levels can be elevated by HIV infection and, therefore, cannot be used reliably to rule out adrenal insufficiency. However, a morning cortisol level of less than 3 to 5 µg/dL highly suggests underlying adrenal insufficiency in all patients.<a class="bibr" href="#article-149535.r73" rid="article-149535.r73">[73]</a> A cortisol level greater than 18 µg/dL 30 or 60 minutes after administration of 250 µg of cosyntropin makes adrenal insufficiency unlikely; cosyntropin is the first 24 amino acids of the N-terminal portion of the intact native ACTH molecule and comprises the biologically active region of intact ACTH. A lower diagnostic threshold for cortisol levels following cosyntropin administration of 14 to 15 µg/dL has been suggested when employing newer monoclonal antibody-based cortisol assays.<a class="bibr" href="#article-149535.r74" rid="article-149535.r74">[74]</a>   </p><p>Imaging is useful to evaluate the adrenal gland for neoplastic or infectious involvement. Adrenal gland enlargement may be seen in fungal infections and early tuberculosis. Adrenal glands may become small and fibrotic in late tuberculosis. Adrenal calcifications may be suggestive of tubercular disease.<a class="bibr" href="#article-149535.r11" rid="article-149535.r11">[11]</a> </p><p>
|
|
<b>Bone Disorders and Osteoporosis</b>
|
|
</p><p>Individuals with HIV should be periodically assessed for osteoporosis risk factors, and serum vitamin D levels should be measured annually. All postmenopausal women, men aged 50 years or greater, and patients with other additional risk factors for osteoporosis should undergo dual x-ray absorptiometry (DEXA) scanning. Even when HIV is included in the risk factors for secondary osteoporosis or adjustment for Trabecular Bone Score (TBS) is made, the Fracture Risk Assessment Tool (FRAX) underestimates the risk of fracture in HIV-infected patients. Patients with documented osteopenia should be screened more regularly, and those with osteoporosis should strongly consider treatment.<a class="bibr" href="#article-149535.r15" rid="article-149535.r15">[15]</a>  </p><p>
|
|
<b>Gonadal Dysfunction</b>
|
|
</p><p>The evaluation of gonadal dysfunction in men hinges on establishing biochemical evidence of low testosterone levels. Serum testosterone should be checked in the early morning in a fasting state; testosterone levels fall naturally during the later part of the day and with food intake. The Endocrine Society recommends confirming low testosterone levels on at least 2 different days due to natural day-to-day variations. Most circulating testosterone is bound to sex hormone-binding globulin (SHBG); a minor fraction is loosely bound to albumin, and the remainder is unbound or "free." Patients with HIV may have increased circulating SHBG, which can increase the total testosterone to within the normal range despite underlying hypogonadism. "Bioavailable testosterone" is the total of free and albumin-bound testosterone; this calculated value is considered a more accurate reflection of testosterone levels. The use of available direct analog-based free testosterone immunoassays is not recommended as they are inaccurate.<a class="bibr" href="#article-149535.r70" rid="article-149535.r70">[70]</a></p><p>If low testosterone levels are associated with low or "inappropriately normal" gonadotropin levels, hypothalamic-pituitary dysfunction should be suspected, and further evaluation with sellar imaging and assessment for other pituitary hormonal deficiencies should be undertaken. However, elevated gonadotropin levels suggest primary testicular dysfunction or primary hypogonadism. These patients should be evaluated for Klinefelter syndrome and testicular involvement by opportunistic infections.  </p><p>
|
|
<b>Growth Hormone Deficiency</b>
|
|
</p><p>Biochemical GH deficiency is defined as inadequate GH response to provocative testing. The GHRH+ARG stimulation test is the most studied provocative test in HIV-infected patients, although the insulin tolerance test is considered the general diagnostic gold standard. An isolated IGF-1 level may be insufficient to diagnose GH deficiency but valuable when provocative test results are inconclusive. </p><p>A GH peak cutoff of 7.5 μg/L on provocative testing is the current diagnostic standard of biochemical GH deficiency in HIV-infected patients. The clinical manifestations and markers of GH deficiency, such as quantification of visceral adiposity, bone mineral density, quality of life scores, and cardiovascular risk, were significantly different in patients on either side of this cutoff value.<a class="bibr" href="#article-149535.r24" rid="article-149535.r24">[24]</a> A GH level above the cutoff essentially rules out GH deficiency.  </p><p>A diagnosis of GH deficiency should only be made when biochemical GH deficiency is documented in the appropriate clinical context;  multiple factors can influence the hormonal response to provocative testing. This is of particular importance in HIV-infected patients in whom reduced GH secretion may be functional. When imaging reveals pituitary or hypothalamic injury or disease and laboratory testing reveals biochemical GH deficiency, true GH deficiency is highly likely.</p><p>
|
|
<b>HIV- and AIDS-Wasting Syndromes</b>
|
|
</p><p>The laboratory evaluation of patients with HIV- or AIDS-wasting syndromes is comprehensive. After the laboratory evaluation, imaging studies may be indicated to evaluate opportunistic infections and hormonal deficiencies.<a class="bibr" href="#article-149535.r30" rid="article-149535.r30">[30]</a> Recommended laboratory testing includes:</p><ul><li class="half_rhythm"><div>CD4 lymphocyte count and HIV viral load to establish overall disease control and underlying risks for opportunistic infections</div></li><li class="half_rhythm"><div>Screening for nutritional deficiencies, including but not limited to iron, vitamin D, calcium, vitamin B12, and folate</div></li><li class="half_rhythm"><div>Testing for gastrointestinal opportunistic infections, as suggested by a comprehensive medical history and physical examination</div></li><li class="half_rhythm"><div>Evaluation for hypogonadism and growth hormone deficiency.</div></li></ul><p>
|
|
<b>Lipodystrophy</b>
|
|
</p><p>The diagnosis of lipodystrophy is predominantly clinical; objective fat quantification via computed tomography, magnetic resonance imaging, or DEXA is limited to research settings.<a class="bibr" href="#article-149535.r32" rid="article-149535.r32">[32]</a> Patients with HIV should be clinically evaluated for lipodystrophy at each clinic visit. Serial anthropometric measurements of height, weight, BMI, waist-to-hip ratio, limb circumference, and skin fold thickness are helpful. The diagnosis of lipodystrophy should prompt a more aggressive evaluation for other metabolic abnormalities, such as dyslipidemia and glucose intolerance, as these metabolic sequelae increase cardiovascular risk.<a class="bibr" href="#article-149535.r32" rid="article-149535.r32">[32]</a></p><p>
|
|
<b>Glucose Intolerance and Diabetes Mellitus</b>
|
|
</p><p>In the general population, diabetes mellitus may be diagnosed when fasting plasma glucose is ≥126 mg/dL, 2-hour plasma glucose is ≥200 mg/dL in a 75-gram oral glucose tolerance test, glycated hemoglobin (HbA1c) is ≥6.5% or random plasma glucose is ≥200 mg/dL in the presence of the classic symptoms of hyperglycemia. A prediabetes diagnosis requires a fasting plasma glucose of 100 to 125 mg/dL, a 2-hour plasma glucose of 140 to 199 mg/dL in a 75-gram oral glucose tolerance test, or HbA1c of 5.7% to 6.4%.</p><p>The Infectious Disease Society of America (IDSA) recommends obtaining fasting plasma glucose and HbA1c before and within 3 months of initiating ART in patients with HIV.<a class="bibr" href="#article-149535.r75" rid="article-149535.r75">[75]</a> However, HbA1c may underestimate the glycemic burden in this population, and a cutoff of 5.8% may be more appropriate for diagnosis of diabetes mellitus.<a class="bibr" href="#article-149535.r76" rid="article-149535.r76">[76]</a><b> </b>Once diagnosed, patients should be evaluated for the micro- and macrovascular complications of diabetes mellitus at least annually.</p><p>
|
|
<b>Lipid Abnormalities</b>
|
|
</p><p>The principal implication of dyslipidemia is an increased risk of cardiovascular disease and associated mortality. The evaluation of patients with HIV and dyslipidemia should be individualized and include the assessment of traditional risk factors such as any personal or family history of cardiovascular disease, individual dietary habits, physical activity levels, personal history of tobacco use, the presence and control of diabetes mellitus, laboratory evaluation of lipid levels, BMI, and waist circumference. The IDSA recommends obtaining a fasting lipid panel before and 3 months after initiating ART with routine evaluation from then on.<a class="bibr" href="#article-149535.r35" rid="article-149535.r35">[35]</a> Specific physical examination findings like tendon, skin, or palmar xanthomas, xanthelasmata, eruptive xanthomas, or lipemia retinalis should prompt an evaluation for an inherited lipid disorder. </p></div><div id="article-149535.s7"><h2 id="_article-149535_s7_">Treatment / Management</h2><p>
|
|
<b>Thyroid Dysfunction</b>
|
|
</p><p>The management of thyroid dysfunction in individuals with HIV is similar to that in those without the infection. The treatment of hypothyroidism entails supplementation with levothyroxine to achieve a serum TSH level between 0.5-2.5 mU/L.<a class="bibr" href="#article-149535.r72" rid="article-149535.r72">[72]</a> Management options for Graves disease include medical therapy with thionamides, radioactive iodine ablation, or surgical resection.<a class="bibr" href="#article-149535.r77" rid="article-149535.r77">[77]</a> Patients taking medications that can increase thyroid hormone clearance may require an increased dose of levothyroxine to achieve the desired physiologic response. Thyroid dysfunction secondary to neoplastic or opportunistic infectious infiltration may normalize with treating those disease processes.</p><p>
|
|
<b>Adrenal Dysfunction</b>
|
|
</p><p>While the treatment of adrenal insufficiency can be life-saving in individuals with HIV, unnecessary treatment can exacerbate underlying infections and increase morbidity and mortality; establishing an accurate diagnosis is crucial. Hydrocortisone can be used in doses ranging from 15 to 30 mg/day in 2 or 3 divided doses. Fludrocortisone 0.05 to 0.2 mg/day can be used for concomitant mineralocorticoid deficiency in primary adrenal insufficiency. Patients should be evaluated regularly for excessive weight gain, particularly the development of central obesity, dependent edema, and hypertension, and doses adjusted to prevent overtreatment.<a class="bibr" href="#article-149535.r67" rid="article-149535.r67">[67]</a></p><p>Hydrocortisone doses should be increased to 2 or 3 times the baseline requirement during periods of physiologic stress, including minor illnesses, or when drugs that increase cortisol clearance, like rifampin or phenytoin, are used. Stress-dose steroids are required during severe illness, major surgery, or adrenal crisis; stress-dose steroids include hydrocortisone 100 mg orally followed by 50 mg orally every 6 hours or a continuous infusion of 200 mg over 24 hours.<a class="bibr" href="#article-149535.r66" rid="article-149535.r66">[66]</a> </p><p>Prednisone and dexamethasone are alternatives to hydrocortisone but carry a higher risk of iatrogenic steroid excess secondary to higher potency and longer duration of action. Dose adjustments may need to be considered for systemic and inhaled glucocorticoids with concomitant use of PIs to reduce the risk of iatrogenic Cushing syndrome.</p><p>
|
|
<b>Bone Disorders and Osteoporosis</b>
|
|
</p><p>Patients with HIV and inadequate intake of dietary calcium should receive supplementation with 800 to 1200 mg of elemental calcium daily. Vitamin D should be supplemented to achieve a serum vitamin D level ≥30 ng/mL. Patients on ART with concomitant osteopenia or osteoporosis may benefit from switching to a bone-friendly ART regimen that utilizes abacavir or tenofovir alafenamide instead of tenofovir disoproxyl fumarate. Bisphosphonates are the recommended pharmacologic therapeutic intervention for established osteoporosis. A single dose of zoledronic acid or alendronate administered 2 weeks before initiating ART and continued for 14 weeks after that has been shown to attenuate the loss of bone mineral density commonly observed during the first two years after initiating ART. There is limited data on the use of denosumab and parathyroid hormone analogs in treating osteoporosis in individuals with HIV.<a class="bibr" href="#article-149535.r15" rid="article-149535.r15">[15]</a>  </p><p>
|
|
<b>Gonadal Dysfunction</b>
|
|
</p><p>Testosterone replacement therapy should be considered in men with symptoms of hypogonadism and unequivocally low testosterone levels. Testosterone replacement therapy has been shown to improve sexual function, lean muscle mass, mood, and bone mineral density. Commonly employed testosterone formulations include intramuscular or subcutaneous testosterone injections, transdermal patches, and gels. Short-term testosterone replacement therapy for 3 to 6 months can be an adjunctive treatment to achieve weight gain and muscle strength in patients with AIDS-wasting syndrome and low testosterone levels.<a class="bibr" href="#article-149535.r57" rid="article-149535.r57">[57]</a><a class="bibr" href="#article-149535.r70" rid="article-149535.r70">[70]</a> </p><p>Hormone replacement therapy with estrogen and progesterone should be considered for women with premature menopause or prolonged amenorrhea to counter the rapid decline in bone mineral density associated with these conditions.<a class="bibr" href="#article-149535.r59" rid="article-149535.r59">[59]</a> </p><p>
|
|
<b>Growth Hormone Deficiency</b>
|
|
</p><p>The management of GH deficiency due to a primary pituitary or hypothalamic disease requires assessing other pituitary hormones, hormone replacement as needed, and disease-specific treatment. GH replacement is indicated for most patients whose onset of GH deficiency occurs in childhood and persists into adulthood. However, for patients with adult-onset GH deficiency, treatment decisions should be made via shared decision-making while considering the high cost and burden of treatment with relatively modest benefits.</p><p>The true significance of reduced GH secretion in HIV-infected patients remains unclear. The studies that established reduced GH secretion in patients with HIV were performed almost exclusively in men and were not correlated with imaging of the pituitary or hypothalamic regions.<a class="bibr" href="#article-149535.r78" rid="article-149535.r78">[78]</a><a class="bibr" href="#article-149535.r79" rid="article-149535.r79">[79]</a> No trials have been conducted to investigate treating HIV-positive patients with biochemical GH deficiency with hormone replacement therapy. </p><p>
|
|
<b>Metabolic Dysfunction</b>
|
|
</p><p>
|
|
<b>HIV- and AIDS-Wasting Syndromes</b>
|
|
</p><p>The management of HIV- and AIDS-wasting syndromes requires diagnosing and treating contributing opportunistic infections and hormonal dysfunction while improving overall caloric intake. Appetite stimulants like dronabinol or megestrol acetate can be considered. Therapy with 0.1 mg/kg/d of r-hGH increases lean muscle mass and body weight.<a class="bibr" href="#article-149535.r30" rid="article-149535.r30">[30]</a><a class="bibr" href="#article-149535.r80" rid="article-149535.r80">[80]</a><a class="bibr" href="#article-149535.r81" rid="article-149535.r81">[81]</a> This regimen has been approved by the United States Food and Drug Administration (FDA) for AIDS-wasting syndrome. In patients with wasting and low testosterone levels, testosterone replacement therapy should be considered. Anabolic steroids like nandrolone have also been shown to increase lean muscle mass and strength.<a class="bibr" href="#article-149535.r30" rid="article-149535.r30">[30]</a> </p><p>
|
|
<b>Lipoatrophy</b>
|
|
</p><p>Facial lipoatrophy may reveal the HIV status of an individual and result in social stigmatization. The fear of lipoatrophy may impact adherence to ART. </p><p>Substituting thymidine NRTIs like stavudine or zidovudine with another NRTI such as tenofovir or abacavir can increase subcutaneous fat but does not fully resolve peripheral lipoatrophy.<a class="bibr" href="#article-149535.r82" rid="article-149535.r82">[82]</a> There appears to be no benefit in switching PIS, nevirapine, or efavirenz.<a class="bibr" href="#article-149535.r83" rid="article-149535.r83">[83]</a><a class="bibr" href="#article-149535.r84" rid="article-149535.r84">[84]</a> Reconstructive therapy with autologous fat transplants, permanent fillers, or injectable bioabsorbable skin fillers, which stimulate local collagen production, is a therapeutic option for lipoatrophy.</p><p>Thiazolidinediones, ligands for peroxisome proliferator activator reception gamma (PPARγ), promote adipocyte differentiation. Although they improved insulin sensitivity, there was no improvement in lipoatrophy.<a class="bibr" href="#article-149535.r82" rid="article-149535.r82">[82]</a><a class="bibr" href="#article-149535.r85" rid="article-149535.r85">[85]</a></p><p>
|
|
<b>Lipohypertrophy</b>
|
|
</p><p>The treatment of lipohypertrophy requires dietary modification and increased physical activity. Metformin may be used as a therapeutic intervention and is particularly beneficial in patients with insulin resistance. However, metformin can also reduce subcutaneous fat and should not be used when there is coincident lipoatrophy.<a class="bibr" href="#article-149535.r82" rid="article-149535.r82">[82]</a></p><p>HIV lipohypertrophy has been treated with GH and GHRH analogs.<a class="bibr" href="#article-149535.r86" rid="article-149535.r86">[86]</a> Recombinant human growth hormone at supraphysiological dosages of 4 mg/d reduced visceral and subcutaneous fat; this regimen was frequently associated with adverse effects such as arthralgias, peripheral edema, carpal tunnel syndrome, and insulin resistance. Physiological doses of r-hGH were better tolerated, but the efficacy in reducing visceral fat was lower, and the effect was lost after treatment discontinuation.<a class="bibr" href="#article-149535.r86" rid="article-149535.r86">[86]</a> </p><p>Tesamorelin is a GHRH analog that increases the endogenous pulsatility of GH secretion, thereby limiting some of the adverse effects of high-dose exogenous GH. Tesamorelin is well-tolerated and can decrease visceral adiposity without affecting subcutaneous fat or insulin sensitivity. While tesamorelin is the only FDA-approved drug approved to treat HIV lipohypertrophy, it is costly, and its benefits reverse when therapy is stopped.<a class="bibr" href="#article-149535.r87" rid="article-149535.r87">[87]</a><a class="bibr" href="#article-149535.r88" rid="article-149535.r88">[88]</a></p><p>
|
|
<b>Glucose Intolerance and Diabetes Mellitus</b>
|
|
</p><p>Managing diabetes mellitus in individuals with HIV is similar to the general population. The target HbA1c for most patients with diabetes mellitus is ≤7%, but should be individualized for each patient. Managing hyperglycemia, preventing the micro- and macrovascular complications of diabetes, and reducing the overall risk of cardiovascular disease requires lifestyle modifications, dietary management, weight loss, and pharmacological therapy.<a class="bibr" href="#article-149535.r89" rid="article-149535.r89">[89]</a><a class="bibr" href="#article-149535.r90" rid="article-149535.r90">[90]</a><a class="bibr" href="#article-149535.r91" rid="article-149535.r91">[91]</a><b> </b></p><p>Patients taking ritonavir, lopinavir, zidovudine, or stavudine with concomitant persistent hyperglycemia despite therapeutic interventions may benefit from switching to an alternate ART regimen; this should only be considered after analyzing the potential of adverse effects and the impact on virological control. The HIV integrase inhibitor dolutegravir increases the concentration of metformin, and the total metformin dose should be limited to 1000 mg daily.<a class="bibr" href="#article-149535.r20" rid="article-149535.r20">[20]</a><b> </b>The risk of lactic acidosis with metformin increases with concomitant use of NRTIs like stavudine and didanosine.</p><p>
|
|
<b>Lipid Abnormalities</b>
|
|
</p><p>Managing lipid abnormalities in patients with HIV requires the regular assessment and minimization of cardiovascular risk. Management of dyslipidemia should be comprehensive, and traditional risk factors like diet, smoking, and physical activity should be addressed at each visit. The management of concomitant diabetes mellitus and hypertension should be optimized. For patients on ART, switching their current regimen to one that is more lipid-friendly may be considered.<a class="bibr" href="#article-149535.r92" rid="article-149535.r92">[92]</a> </p><p>The decision to initiate pharmacotherapy for dyslipidemia can be made by employing multivariate models like the American Heart Association/American College of Cardiology (AHA/ACC) risk calculator and Data Collection on the Adverse Effects of Anti-HIV Drugs (DAD) risk calculator. However, these models typically underestimate the risk of dyslipidemia in patients with HIV.</p><p>Statins are the drugs of choice when pharmacological therapy for dyslipidemia is warranted. Because of the potential for drug interactions with ART, the choice of statin should be carefully considered. Many statins are metabolized by CYP3A4, which is inhibited by PIs and cobicistat, resulting in supratherapeutic statin concentrations and associated adverse effects. </p><p>However, CYP3A4 does not metabolize pitavastatin, pravastatin, or fluvastatin, and these medications can be safely used with various ART regimens.<a class="bibr" href="#article-149535.r93" rid="article-149535.r93">[93]</a> In a recent study, pitavastatin demonstrated a decreased risk of cardiovascular complications in patients with HIV.<a class="bibr" href="#article-149535.r94" rid="article-149535.r94">[94]</a> CYP3A4 also does not metabolize rosuvastatin, but, per the manufacturer, rosuvastatin levels can increase by 5- to 7-fold when it is used concomitantly with lopinavir-ritonavir or ritonavir-boosted atazanavir. If used with these ART regimens, rosuvastatin should be started at a low dose of 5 or 10 mg.</p><p>Atorvastatin is partially metabolized through CYP3A4; atorvastatin levels can double when used with PIs. If atorvastatin is to be used in conjunction with PIs, it should be started at a lower dose, and dosages of 80 mg/d should be avoided. Simvastatin and lovastatin are highly metabolized through CYP3A4 and should not be used concomitantly with PIs.<a class="bibr" href="#article-149535.r95" rid="article-149535.r95">[95]</a></p><p>Fibrates may be used to treat triglyceride elevations >500 mg/dL to reduce the risk of pancreatitis; fibrates have not been shown to improve the increased cardiovascular risk associated with hypertriglyceridemia.<a class="bibr" href="#article-149535.r96" rid="article-149535.r96">[96]</a> Fenofibrate is the most commonly used medication of this class due to its reduced propensity for drug interactions. On the other hand, omega-3 fatty acids may be used to manage hypertriglyceridemia with a good safety profile, and recent studies showed they reduced secondary ischemic episodes in patients with previous coronary artery disease.<a class="bibr" href="#article-149535.r97" rid="article-149535.r97">[97]</a></p></div><div id="article-149535.s8"><h2 id="_article-149535_s8_">Differential Diagnosis</h2><p>
|
|
<b>Thyroid Dysfunction</b>
|
|
</p><p>The differential diagnosis of thyroid dysfunction in patients with HIV includes iodine deficiency, autoimmune thyroiditis unrelated to HIV infection, subacute granulomatous thyroiditis, painless thyroiditis, postpartum thyroiditis, Graves disease, toxic thyroid adenoma, and toxic multinodular goiter.<a class="bibr" href="#article-149535.r72" rid="article-149535.r72">[72]</a><a class="bibr" href="#article-149535.r98" rid="article-149535.r98">[98]</a>  </p><p>
|
|
<b>Adrenal Dysfunction</b>
|
|
</p><p>After a diagnosis of adrenal insufficiency is made in a patient with HIV, causes of secondary adrenal insufficiency must be considered. Secondary adrenal insufficiency may occur due to exogenous steroid use or involvement of the pituitary gland or hypothalamus by systemic diseases or local processes, including neoplasia, infections, and inflammatory disorders.<a class="bibr" href="#article-149535.r67" rid="article-149535.r67">[67]</a></p><p>
|
|
<b>Bone Disorders and Osteoporosis</b>
|
|
</p><p>Patients with HIV and a fragility fracture must have diagnoses such as malignancy, fibrous dysplasia, and other bony lesions excluded. Causes of secondary osteoporosis necessitate specific treatment and should also be excluded, including hyperthyroidism, hyperparathyroidism, hypogonadism, Cushing syndrome, osteomalacia, inflammatory bowel disease, and malabsorption. A detailed review of prescription and nonprescription medications should be performed to identify drugs that can contribute to osteoporosis.<a class="bibr" href="#article-149535.r99" rid="article-149535.r99">[99]</a><a class="bibr" href="#article-149535.r100" rid="article-149535.r100">[100]</a></p><p>
|
|
<b>Gonadal Dysfunction</b>
|
|
</p><p>The sexual dysfunction and other symptoms of hypogonadism in men are nonspecific. In addition to hypogonadism, factors such as HIV-related psychosocial issues, fear of HIV transmission, drug use, body image in AIDS-wasting syndrome, or lipodystrophy can all contribute to sexual dysfunction independent of testosterone levels. </p><p>Established adult-onset primary hypogonadism is most frequently due to Klinefelter syndrome, myotonic dystrophy, or bilateral varicoceles. Secondary hypogonadism may be secondary to morbid obesity, excessive alcohol use, critical illness, extreme weight loss unrelated to HIV, opiates, glucocorticoids, diabetes mellitus, hyperprolactinemia, tumors, or inflammatory and infiltrative disorders of the hypothalamic-pituitary region.<a class="bibr" href="#article-149535.r57" rid="article-149535.r57">[57]</a></p><p>
|
|
<b>Growth Hormone Deficiency</b>
|
|
</p><p>Growth hormone deficiency can be caused by multiple disorders involving the pituitary and hypothalamus. These disorders include pituitary tumors; extra pituitary tumors such as craniopharyngioma or metastatic disease; infiltrative disorders including Langerhans cell histiocytosis, sarcoidosis, or hemochromatosis; tubercular, bacterial, or fungal infections; hypophysitis; surgery or radiation of the sellar region; pituitary infarction or apoplexy; cerebrovascular accidents including subarachnoid hemorrhage; and genetic abnormalities causing congenital hormonal deficiencies.<a class="bibr" href="#article-149535.r101" rid="article-149535.r101">[101]</a> </p><p>
|
|
<b>Metabolic Dysfunction</b>
|
|
</p><p>
|
|
<b>HIV- and AIDS-Wasting Syndromes</b>
|
|
</p><p>Disorders of various organ systems can cause weight loss irrespective of HIV status. Malignancy is a common cause of weight loss, as are gastrointestinal malabsorptive disorders such as celiac disease. Several endocrinopathies, including hyperthyroidism and adrenal insufficiency, can induce profound weight loss. Advanced heart failure and end-stage renal disease may also cause wasting. Alcohol use disorder and substance use disorders, particularly involving stimulants such as cocaine, may also cause weight loss.</p><p>
|
|
<b>Lipoatrophy and Lipohypertrophy</b>
|
|
</p><p>The primary differential diagnosis for lipoatrophy is AIDS-wasting syndrome; other causes of unintentional weight loss or wasting should be considered. Weight gain due to common and rare conditions can mimic lipohypertrophy. These conditions include but are not limited to physical inactivity with excess calorie intake, endocrinopathies such as polycystic ovarian syndrome, hypothyroidism, and Cushing syndrome, and the use of medications such as antiepileptics, antipsychotics, and antidepressants.</p><p>
|
|
<b>Glucose Intolerance and Diabetes Mellitus</b>
|
|
</p><p>Diabetes mellitus can be secondary to disorders or drugs unrelated to HIV status that may need to be considered based on clinical suspicion.<a class="bibr" href="#article-149535.r102" rid="article-149535.r102">[102]</a> Genetic disorders of pancreatic beta cell function or insulin action can induce glucose intolerance. Disorders affecting the exocrine pancreas, such as pancreatitis, cystic fibrosis, hemochromatosis, or malignancy, can cause glucose intolerance or frank diabetes. Cushing syndrome, acromegaly, and hyperthyroidism are common endocrinopathies that may cause glucose intolerance or frank diabetes mellitus. Glucose intolerance is a common adverse effect of prolonged antipsychotic, glucocorticoid, and thiazide use.</p><p>
|
|
<b>Lipid Abnormalities</b>
|
|
</p><p>The presence of severe hyperlipidemia and a strong family history of hyperlipidemia or premature cardiovascular disease should raise the clinical suspicion of familial syndromes. Secondary causes of hyperlipidemia like diabetes mellitus, obesity, excessive alcohol consumption, hypothyroidism, nephrotic syndrome, chronic kidney disease, and medications like thiazides, beta blockers, glucocorticoids, estrogen preparations, and antipsychotics should also be considered.<a class="bibr" href="#article-149535.r103" rid="article-149535.r103">[103]</a></p></div><div id="article-149535.s9"><h2 id="_article-149535_s9_">Prognosis</h2><p>
|
|
<b>Thyroid Dysfunction</b>
|
|
</p><p>With appropriate treatment, the prognosis of thyroid dysfunction in individuals with HIV is similar to those without HIV. </p><p>
|
|
<b>Adrenal Dysfunction</b>
|
|
</p><p>Treatment of adrenal insufficiency can be life-saving in patients with HIV. On the contrary, unnecessary treatment can exacerbate underlying infections and increase morbidity and mortality. As adrenal insufficiency is primarily secondary to opportunistic infections or neoplasia, its presence can signal advanced AIDS.<a class="bibr" href="#article-149535.r10" rid="article-149535.r10">[10]</a><a class="bibr" href="#article-149535.r11" rid="article-149535.r11">[11]</a> </p><p>
|
|
<b>Bone Disorders and Osteoporosis</b>
|
|
</p><p>Fragility fractures occur about 10 years earlier in patients infected with HIV compared to the general population. Switching to a bone-friendly ART regimen reduces the rate of bone loss, but it is unknown if there is a decrease in fracture incidence. Treating osteoporosis in HIV-infected patients with bisphosphonates yields an improvement in bone mineral density similar to that of the general population; there have been no long-term studies to indicate this reduces the incidence of fracture. </p><p>
|
|
<b>Gonadal Dysfunction</b>
|
|
</p><p>Hypogonadism in individuals with HIV who are not on ART can be a sign of advanced AIDS and an overall poor prognosis. However, outcomes may vary with the underlying cause of hypogonadism. Secondary hypogonadism from neoplastic or infectious involvement of the pituitary region may have a worse prognosis than most primary hypogonadism etiologies. Testosterone replacement therapy can positively affect quality of life by improving sexual function, mood, muscle mass and strength, and bone mineral density.<a class="bibr" href="#article-149535.r15" rid="article-149535.r15">[15]</a> </p><p>
|
|
<b>Growth Hormone Deficiency</b>
|
|
</p><p>In general, replacing GH in patients with true deficiency is associated with increased lean muscle mass, decreased fat mass, and improved quality of life. Improvement in bone mineral density with GH replacement was noted in men but not women for unclear reasons.<a class="bibr" href="#article-149535.r104" rid="article-149535.r104">[104]</a> Studies of the effect of GH on lipid profiles revealed conflicting results. Improvement in specific cardiac function parameters, such as left ventricular mass and stroke volume, has been demonstrated, but data on mortality is limited.<a class="bibr" href="#article-149535.r105" rid="article-149535.r105">[105]</a></p><p>Patients with GH deficiency secondary to hypopituitarism have increased all-cause mortality that persists despite hormone replacement.<a class="bibr" href="#article-149535.r106" rid="article-149535.r106">[106]</a><a class="bibr" href="#article-149535.r107" rid="article-149535.r107">[107]</a> There are no current studies investigating the treatment of individuals with HIV and biochemical GH deficiency with hormone replacement. </p><p>
|
|
<b>Metabolic Dysfunction</b>
|
|
</p><p>
|
|
<b>HIV- and AIDS-Wasting Syndromes</b>
|
|
</p><p>In patients with wasting syndromes, the magnitude of weight loss directly correlates with the risk of death. Despite a significant overall decrease in mortality associated with HIV after the introduction of ART,  HIV-associated wasting remains a considerable concern. Even in patients on ART, weight loss of >10% from the baseline or previous visit is associated with a 4- to 6-fold increase in mortality.<a class="bibr" href="#article-149535.r108" rid="article-149535.r108">[108]</a></p><p>
|
|
<b>Disorders of Glucose and Lipid Metabolism and Fat Distribution</b>
|
|
</p><p>Individuals with HIV are at a higher risk for developing various metabolic abnormalities. This risk has been attributed directly to HIV, the natural course of the disease, and the use of ART.<a class="bibr" href="#article-149535.r109" rid="article-149535.r109">[109]</a> The increased incidence of metabolic complications increases the risk for atherosclerosis and associated cardiovascular complications. The Veterans Aging Cohort Study demonstrated a 50% increase in the risk of acute myocardial infarction in individuals with HIV compared to the non-HIV population over a 6-year study period.<a class="bibr" href="#article-149535.r110" rid="article-149535.r110">[110]</a> ART has changed the course of the HIV pandemic and dramatically improved the lifespan of patients with HIV.<a class="bibr" href="#article-149535.r111" rid="article-149535.r111">[111]</a> However, even with early treatment, a significant gap in life expectancy persists between individuals with and without HIV.<a class="bibr" href="#article-149535.r112" rid="article-149535.r112">[112]</a></p></div><div id="article-149535.s10"><h2 id="_article-149535_s10_">Complications</h2><p>
|
|
<b>Thyroid Dysfunction</b>
|
|
</p><p>Uncontrolled hypothyroidism may cause anemia, electrolyte abnormalities, dyslipidemia, hypertension, and increased overall cardiovascular mortality. Myxedema coma is the result of severe, longstanding, untreated hypothyroidism, is characterized by symptoms secondary to decreased metabolism in multiple organs, and is associated with a high mortality rate.<a class="bibr" href="#article-149535.r113" rid="article-149535.r113">[113]</a> </p><p>The thyrotoxicosis of uncontrolled hyperthyroidism can cause arrhythmias, heart failure, and osteoporosis. Thyroid storm is a life-threatening thyrotoxic state frequently precipitated by another illness, surgery, or similar physiologic stressor.<a class="bibr" href="#article-149535.r114" rid="article-149535.r114">[114]</a></p><p>All types of thyroid dysfunction can adversely affect menstrual cycles, fertility, and pregnancy outcomes.</p><p>
|
|
<b>Adrenal Dysfunction</b>
|
|
</p><p>Without adequate treatment, acute adrenal insufficiency causes death from cardiovascular collapse.<a class="bibr" href="#article-149535.r67" rid="article-149535.r67">[67]</a> Chronic adrenal insufficiency is associated with weight loss, its associated complications, and lower overall quality of life.<a class="bibr" href="#article-149535.r66" rid="article-149535.r66">[66]</a> Cushing syndrome increases the risk of glucose intolerance, hypertension, hyperlipidemia, osteoporosis, and cardiovascular disease.</p><p>
|
|
<b>Bone Disorders and Osteoporosis</b>
|
|
</p><p>The most important clinical consequence of osteoporosis is a fracture. Vertebral fractures, followed by hip and forearm fractures, are the most commonly seen. Fractures are associated with significant pain, disability, reduced quality of life, and increased risk of all-cause mortality.<a class="bibr" href="#article-149535.r15" rid="article-149535.r15">[15]</a>  </p><p>
|
|
<b>Gonadal Dysfunction</b>
|
|
</p><p>Hypogonadism is associated with sexual dysfunction, weight loss, a decreased sense of well-being, and overall poor quality of life. Hypogonadism causes osteoporosis and increases the risk of fragility fractures. Independent of HIV status, mortality is increased in men with hypogonadism. Data is mixed regarding a potential increase in overall cardiovascular risk with testosterone replacement therapy, especially in older men. In a recent randomized placebo-controlled trial, middle-aged and older men with a high risk for or known cardiovascular disease who received testosterone did not have a higher incidence of cardiovascular adverse events.<a class="bibr" href="#article-149535.r115" rid="article-149535.r115">[115]</a></p><p>Testosterone replacement therapy can cause erythrocytosis, increase LDL, worsen sleep apnea, and increase the risk for venous thromboembolism. There is no definitive evidence that testosterone replacement therapy increases the risk of developing prostate cancer. However, it is recommended that men 40 years and older with an elevated baseline risk of prostate cancer and all men older than 50 years should be monitored closely with serum prostate-specific antigen after initiating testosterone replacement therapy. </p><p>
|
|
<b>Growth Hormone Deficiency</b>
|
|
</p><p>Patients with the onset of GH deficiency in childhood are at significantly increased risk of short stature. All patients with GH deficiency are at increased risk of reduced bone mineral density with resulting fractures, reduced lean muscle mass, and increased fat mass. Patients with GH deficiency routinely score lower on quality-of-life questionnaires than their healthy counterparts.<a class="bibr" href="#article-149535.r116" rid="article-149535.r116">[116]</a></p><p>
|
|
<b>Metabolic Dysfunction</b>
|
|
</p><p>
|
|
<b>HIV- and AIDS-Wasting Syndromes</b>
|
|
</p><p>In addition to the increased risk of mortality, patients with these syndromes are at increased risk for nutritional deficiencies, osteoporosis, and fractures. Patients with HIV- or AIDS-wasting syndromes consistently score lower on health-related quality-of-life measures.<a class="bibr" href="#article-149535.r30" rid="article-149535.r30">[30]</a> </p><p>
|
|
<b>Disorders of Fat Distribution, Glucose, and Lipid Metabolism</b>
|
|
</p><p>Lipodystrophy is associated with dyslipidemia, insulin resistance, and chronic systemic inflammation, which can increase overall cardiovascular disease risk. Body fat distribution abnormalities can lead to stigmatization, affecting self-esteem and quality of life.<a class="bibr" href="#article-149535.r32" rid="article-149535.r32">[32]</a> </p><p>The complications of diabetes mellitus are manifold and include cerebrovascular disease, cardiovascular disease, chronic kidney disease, peripheral vascular disease, and diabetic retinopathy. Dyslipidemia increases the risk of atherosclerosis and associated vascular complications.<a class="bibr" href="#article-149535.r117" rid="article-149535.r117">[117]</a> Severe hypertriglyceridemia can cause pancreatitis.  </p></div><div id="article-149535.s11"><h2 id="_article-149535_s11_">Deterrence and Patient Education</h2><p>Individuals with HIV should be educated regarding their increased risk of endocrinologic dysfunction and cardiovascular disease. Despite HIV being an independent risk factor, traditional risk factors remain strong predictors of cardiovascular disease risk in this population. Hence, the optimal approach to cardiovascular risk reduction includes lifestyle interventions such as smoking cessation, dietary intervention, physical activity, weight control, and avoidance of excessive alcohol consumption. </p></div><div id="article-149535.s12"><h2 id="_article-149535_s12_">Enhancing Healthcare Team Outcomes </h2><p>Individuals living with HIV are at an increased risk for developing many endocrinopathies compared to the general population. The clinical presentation of hormonal dysfunction is frequently nonspecific and overlaps with that of HIV infection itself. A high index of clinical suspicion and careful coordination by primary care, infectious disease, cardiology, and endocrinology specialists is needed to diagnose and manage endocrinologic dysfunction appropriately.</p><p>Measuring hormone levels is the most basic and indispensable part of evaluating any endocrine abnormality. An awareness of the unique effects of HIV status on hormone levels helps prevent misdiagnosis. Close attention should be paid to potential drug interactions between antiretrovirals and medications used to treat endocrinologic dysfunction. Pharmacists are indispensable in guiding patients and practitioners through various antiretroviral-induced adverse effects.</p><p>Complications related to advanced HIV and immunocompromise are no longer common in developed countries due to the widespread use of ART. However, HIV status and treatment with ART increase the risk for metabolic complications and cardiovascular disease. The currently available risk calculators underestimate the risk of cardiovascular disease despite considering HIV as an independent risk factor. This raises the need for aggressive preventative measures. </p></div><div id="article-149535.s13"><h2 id="_article-149535_s13_">Review Questions</h2><ul><li class="half_rhythm"><div>
|
|
<a href="https://www.statpearls.com/account/trialuserreg/?articleid=149535&utm_source=pubmed&utm_campaign=reviews&utm_content=149535" ref="pagearea=body&targetsite=external&targetcat=link&targettype=uri">Access free multiple choice questions on this topic.</a>
|
|
</div></li><li class="half_rhythm"><div>
|
|
<a href="https://mdsearchlight.com/infectious-disease/hiv-related-endocrinopathies/?utm_source=pubmedlink&utm_campaign=MDS&utm_content=149535" ref="pagearea=body&targetsite=external&targetcat=link&targettype=uri">Click here for a simplified version.</a>
|
|
</div></li><li class="half_rhythm"><div>
|
|
<a href="https://www.statpearls.com/articlelibrary/commentarticle/149535/?utm_source=pubmed&utm_campaign=comments&utm_content=149535" ref="pagearea=body&targetsite=external&targetcat=link&targettype=uri">Comment on this article.</a>
|
|
</div></li></ul></div><div class="floats-group" id="article-149535.s14"><div class="iconblock whole_rhythm clearfix ten_col fig" id="figarticle149535imagef1" co-legend-rid="figlgndarticle149535imagef1"><a href="/books/NBK599549/figure/article-149535.image.f1/?report=objectonly" target="object" title="Figure" class="img_link icnblk_img figpopup" rid-figpopup="figarticle149535imagef1" rid-ob="figobarticle149535imagef1"><img class="small-thumb" src="/books/NBK599549/bin/graves__orbitopathy.gif" src-large="/books/NBK599549/bin/graves__orbitopathy.jpg" alt="Image " /></a><div class="icnblk_cntnt" id="figlgndarticle149535imagef1"><h4 id="article-149535.image.f1"><a href="/books/NBK599549/figure/article-149535.image.f1/?report=objectonly" target="object" rid-ob="figobarticle149535imagef1">Figure</a></h4><p class="float-caption no_bottom_margin">Graves orbitopathy Image courtesy S Bhimji MD </p></div></div></div><div id="article-149535.s15"><h2 id="_article-149535_s15_">References</h2><dl class="temp-labeled-list"><dl class="bkr_refwrap"><dt>1.</dt><dd><div class="bk_ref" id="article-149535.r1">Ergin HE, Inga EE, Maung TZ, Javed M, Khan S. HIV, Antiretroviral Therapy and Metabolic Alterations: A Review. <span><span class="ref-journal">Cureus. </span>2020 May 11;<span class="ref-vol">12</span>(5):e8059.</span> [<a href="/pmc/articles/PMC7286589/" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pmc">PMC free article<span class="bk_prnt">: PMC7286589</span></a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/32537277" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 32537277</span></a>]</div></dd></dl><dl class="bkr_refwrap"><dt>2.</dt><dd><div class="bk_ref" id="article-149535.r2">Antiretroviral Therapy Cohort Collaboration. Survival of HIV-positive patients starting antiretroviral therapy between 1996 and 2013: a collaborative analysis of cohort studies. <span><span class="ref-journal">Lancet HIV. </span>2017 Aug;<span class="ref-vol">4</span>(8):e349-e356.</span> [<a href="/pmc/articles/PMC5555438/" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pmc">PMC free article<span class="bk_prnt">: PMC5555438</span></a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/28501495" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 28501495</span></a>]</div></dd></dl><dl class="bkr_refwrap"><dt>3.</dt><dd><div class="bk_ref" id="article-149535.r3">Hoffmann CJ, Brown TT. Thyroid function abnormalities in HIV-infected patients. <span><span class="ref-journal">Clin Infect Dis. </span>2007 Aug 15;<span class="ref-vol">45</span>(4):488-94.</span> [<a href="https://pubmed.ncbi.nlm.nih.gov/17638201" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 17638201</span></a>]</div></dd></dl><dl class="bkr_refwrap"><dt>4.</dt><dd><div class="bk_ref" id="article-149535.r4">Nelson M, Powles T, Zeitlin A, Sen P, Scourfield A, Bower M, Gazzard B, Stebbing J. Thyroid dysfunction and relationship to antiretroviral therapy in HIV-positive individuals in the HAART era. <span><span class="ref-journal">J Acquir Immune Defic Syndr. </span>2009 Jan 01;<span class="ref-vol">50</span>(1):113-4.</span> [<a href="https://pubmed.ncbi.nlm.nih.gov/19092451" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 19092451</span></a>]</div></dd></dl><dl class="bkr_refwrap"><dt>5.</dt><dd><div class="bk_ref" id="article-149535.r5">Chen F, Day SL, Metcalfe RA, Sethi G, Kapembwa MS, Brook MG, Churchill D, de Ruiter A, Robinson S, Lacey CJ, Weetman AP. Characteristics of autoimmune thyroid disease occurring as a late complication of immune reconstitution in patients with advanced human immunodeficiency virus (HIV) disease. <span><span class="ref-journal">Medicine (Baltimore). </span>2005 Mar;<span class="ref-vol">84</span>(2):98-106.</span> [<a href="https://pubmed.ncbi.nlm.nih.gov/15758839" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 15758839</span></a>]</div></dd></dl><dl class="bkr_refwrap"><dt>6.</dt><dd><div class="bk_ref" id="article-149535.r6">Micali C, Russotto Y, Celesia BM, Santoro L, Marino A, Pellicanò GF, Nunnari G, Venanzi Rullo E. Thyroid Diseases and Thyroid Asymptomatic Dysfunction in People Living With HIV. <span><span class="ref-journal">Infect Dis Rep. </span>2022 Sep 01;<span class="ref-vol">14</span>(5):655-667.</span> [<a href="/pmc/articles/PMC9498502/" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pmc">PMC free article<span class="bk_prnt">: PMC9498502</span></a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/36136821" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 36136821</span></a>]</div></dd></dl><dl class="bkr_refwrap"><dt>7.</dt><dd><div class="bk_ref" id="article-149535.r7">Bons J, Moreau L, Lefebvre H. Adrenal disorders in human immunodeficiency virus (HIV) infected patients. <span><span class="ref-journal">Ann Endocrinol (Paris). </span>2013 Dec;<span class="ref-vol">74</span>(5-6):508-14.</span> [<a href="https://pubmed.ncbi.nlm.nih.gov/24262982" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 24262982</span></a>]</div></dd></dl><dl class="bkr_refwrap"><dt>8.</dt><dd><div class="bk_ref" id="article-149535.r8">Nassoro DD, Mkhoi ML, Sabi I, Meremo AJ, Lawala PS, Mwakyula IH. Adrenal Insufficiency: A Forgotten Diagnosis in HIV/AIDS Patients in Developing Countries. <span><span class="ref-journal">Int J Endocrinol. </span>2019;<span class="ref-vol">2019</span>:2342857.</span> [<a href="/pmc/articles/PMC6612386/" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pmc">PMC free article<span class="bk_prnt">: PMC6612386</span></a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/31341472" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 31341472</span></a>]</div></dd></dl><dl class="bkr_refwrap"><dt>9.</dt><dd><div class="bk_ref" id="article-149535.r9">Mirani M, Elenkov I, Volpi S, Hiroi N, Chrousos GP, Kino T. HIV-1 protein Vpr suppresses IL-12 production from human monocytes by enhancing glucocorticoid action: potential implications of Vpr coactivator activity for the innate and cellular immunity deficits observed in HIV-1 infection. <span><span class="ref-journal">J Immunol. </span>2002 Dec 01;<span class="ref-vol">169</span>(11):6361-8.</span> [<a href="https://pubmed.ncbi.nlm.nih.gov/12444143" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 12444143</span></a>]</div></dd></dl><dl class="bkr_refwrap"><dt>10.</dt><dd><div class="bk_ref" id="article-149535.r10">Mayo J, Collazos J, Martínez E, Ibarra S. Adrenal function in the human immunodeficiency virus-infected patient. <span><span class="ref-journal">Arch Intern Med. </span>2002 May 27;<span class="ref-vol">162</span>(10):1095-8.</span> [<a href="https://pubmed.ncbi.nlm.nih.gov/12020177" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 12020177</span></a>]</div></dd></dl><dl class="bkr_refwrap"><dt>11.</dt><dd><div class="bk_ref" id="article-149535.r11">Chrousos GP, Zapanti ED. Hypothalamic-pituitary-adrenal axis in HIV infection and disease. <span><span class="ref-journal">Endocrinol Metab Clin North Am. </span>2014 Sep;<span class="ref-vol">43</span>(3):791-806.</span> [<a href="https://pubmed.ncbi.nlm.nih.gov/25169568" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 25169568</span></a>]</div></dd></dl><dl class="bkr_refwrap"><dt>12.</dt><dd><div class="bk_ref" id="article-149535.r12">Chen F, Kearney T, Robinson S, Daley-Yates PT, Waldron S, Churchill DR. Cushing's syndrome and severe adrenal suppression in patients treated with ritonavir and inhaled nasal fluticasone. <span><span class="ref-journal">Sex Transm Infect. </span>1999 Aug;<span class="ref-vol">75</span>(4):274.</span> [<a href="https://pubmed.ncbi.nlm.nih.gov/10615321" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 10615321</span></a>]</div></dd></dl><dl class="bkr_refwrap"><dt>13.</dt><dd><div class="bk_ref" id="article-149535.r13">Brown TT, Qaqish RB. Antiretroviral therapy and the prevalence of osteopenia and osteoporosis: a meta-analytic review. <span><span class="ref-journal">AIDS. </span>2006 Nov 14;<span class="ref-vol">20</span>(17):2165-74.</span> [<a href="https://pubmed.ncbi.nlm.nih.gov/17086056" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 17086056</span></a>]</div></dd></dl><dl class="bkr_refwrap"><dt>14.</dt><dd><div class="bk_ref" id="article-149535.r14">Baranek B, Wang S, Cheung AM, Mishra S, Tan DH. The effect of tenofovir disoproxil fumarate on bone mineral density: a systematic review and meta-analysis. <span><span class="ref-journal">Antivir Ther. </span>2020;<span class="ref-vol">25</span>(1):21-32.</span> [<a href="https://pubmed.ncbi.nlm.nih.gov/32077867" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 32077867</span></a>]</div></dd></dl><dl class="bkr_refwrap"><dt>15.</dt><dd><div class="bk_ref" id="article-149535.r15">Biver E. Osteoporosis and HIV Infection. <span><span class="ref-journal">Calcif Tissue Int. </span>2022 May;<span class="ref-vol">110</span>(5):624-640.</span> [<a href="/pmc/articles/PMC9013331/" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pmc">PMC free article<span class="bk_prnt">: PMC9013331</span></a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/35098324" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 35098324</span></a>]</div></dd></dl><dl class="bkr_refwrap"><dt>16.</dt><dd><div class="bk_ref" id="article-149535.r16">Jacobson MA, Gambertoglio JG, Aweeka FT, Causey DM, Portale AA. Foscarnet-induced hypocalcemia and effects of foscarnet on calcium metabolism. <span><span class="ref-journal">J Clin Endocrinol Metab. </span>1991 May;<span class="ref-vol">72</span>(5):1130-5.</span> [<a href="https://pubmed.ncbi.nlm.nih.gov/1827127" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 1827127</span></a>]</div></dd></dl><dl class="bkr_refwrap"><dt>17.</dt><dd><div class="bk_ref" id="article-149535.r17">Kuehn EW, Anders HJ, Bogner JR, Obermaier J, Goebel FD, Schlöndorff D. Hypocalcaemia in HIV infection and AIDS. <span><span class="ref-journal">J Intern Med. </span>1999 Jan;<span class="ref-vol">245</span>(1):69-73.</span> [<a href="https://pubmed.ncbi.nlm.nih.gov/10095819" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 10095819</span></a>]</div></dd></dl><dl class="bkr_refwrap"><dt>18.</dt><dd><div class="bk_ref" id="article-149535.r18">Kim SJ, Peluso MJ, Wang Y, Bikle D, Shoback D, Kim S. Rapid onset of hypercalcemia from high-grade lymphoma in the setting of HIV-related immune reconstitution inflammatory syndrome. <span><span class="ref-journal">Bone Rep. </span>2019 Jun;<span class="ref-vol">10</span>:100194.</span> [<a href="/pmc/articles/PMC6319307/" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pmc">PMC free article<span class="bk_prnt">: PMC6319307</span></a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/30627599" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 30627599</span></a>]</div></dd></dl><dl class="bkr_refwrap"><dt>19.</dt><dd><div class="bk_ref" id="article-149535.r19">Wong N, Levy M, Stephenson I. Hypogonadism in the HIV-Infected Man. <span><span class="ref-journal">Curr Treat Options Infect Dis. </span>2017;<span class="ref-vol">9</span>(1):104-116.</span> [<a href="/pmc/articles/PMC5346114/" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pmc">PMC free article<span class="bk_prnt">: PMC5346114</span></a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/28344518" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 28344518</span></a>]</div></dd></dl><dl class="bkr_refwrap"><dt>20.</dt><dd><div class="bk_ref" id="article-149535.r20">Mirza FS, Luthra P, Chirch L. Endocrinological aspects of HIV infection. <span><span class="ref-journal">J Endocrinol Invest. </span>2018 Aug;<span class="ref-vol">41</span>(8):881-899.</span> [<a href="https://pubmed.ncbi.nlm.nih.gov/29313284" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 29313284</span></a>]</div></dd></dl><dl class="bkr_refwrap"><dt>21.</dt><dd><div class="bk_ref" id="article-149535.r21">Conde DM, Silva ET, Amaral WN, Finotti MF, Ferreira RG, Costa-Paiva L, Pinto-Neto AM. HIV, reproductive aging, and health implications in women: a literature review. <span><span class="ref-journal">Menopause. </span>2009 Jan-Feb;<span class="ref-vol">16</span>(1):199-213.</span> [<a href="https://pubmed.ncbi.nlm.nih.gov/18800017" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 18800017</span></a>]</div></dd></dl><dl class="bkr_refwrap"><dt>22.</dt><dd><div class="bk_ref" id="article-149535.r22">Cejtin HE, Kalinowski A, Bacchetti P, Taylor RN, Watts DH, Kim S, Massad LS, Preston-Martin S, Anastos K, Moxley M, Minkoff HL. Effects of human immunodeficiency virus on protracted amenorrhea and ovarian dysfunction. <span><span class="ref-journal">Obstet Gynecol. </span>2006 Dec;<span class="ref-vol">108</span>(6):1423-31.</span> [<a href="https://pubmed.ncbi.nlm.nih.gov/17138776" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 17138776</span></a>]</div></dd></dl><dl class="bkr_refwrap"><dt>23.</dt><dd><div class="bk_ref" id="article-149535.r23">Yalamanchi S, Dobs A, Greenblatt RM. Gonadal function and reproductive health in women with human immunodeficiency virus infection. <span><span class="ref-journal">Endocrinol Metab Clin North Am. </span>2014 Sep;<span class="ref-vol">43</span>(3):731-41.</span> [<a href="/pmc/articles/PMC4151241/" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pmc">PMC free article<span class="bk_prnt">: PMC4151241</span></a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/25169564" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 25169564</span></a>]</div></dd></dl><dl class="bkr_refwrap"><dt>24.</dt><dd><div class="bk_ref" id="article-149535.r24">Rochira V, Guaraldi G. Growth hormone deficiency and human immunodeficiency virus. <span><span class="ref-journal">Best Pract Res Clin Endocrinol Metab. </span>2017 Feb;<span class="ref-vol">31</span>(1):91-111.</span> [<a href="https://pubmed.ncbi.nlm.nih.gov/28477736" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 28477736</span></a>]</div></dd></dl><dl class="bkr_refwrap"><dt>25.</dt><dd><div class="bk_ref" id="article-149535.r25">Stanley TL, Grinspoon SK. GH/GHRH axis in HIV lipodystrophy. <span><span class="ref-journal">Pituitary. </span>2009;<span class="ref-vol">12</span>(2):143-52.</span> [<a href="https://pubmed.ncbi.nlm.nih.gov/18270841" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 18270841</span></a>]</div></dd></dl><dl class="bkr_refwrap"><dt>26.</dt><dd><div class="bk_ref" id="article-149535.r26">Youssef J, Sadera R, Mital D, Ahmed MH. HIV and the Pituitary Gland: Clinical and Biochemical Presentations. <span><span class="ref-journal">J Lab Physicians. </span>2021 Mar;<span class="ref-vol">13</span>(1):84-90.</span> [<a href="/pmc/articles/PMC8154342/" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pmc">PMC free article<span class="bk_prnt">: PMC8154342</span></a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/34054243" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 34054243</span></a>]</div></dd></dl><dl class="bkr_refwrap"><dt>27.</dt><dd><div class="bk_ref" id="article-149535.r27">Mangili A, Murman DH, Zampini AM, Wanke CA. Nutrition and HIV infection: review of weight loss and wasting in the era of highly active antiretroviral therapy from the nutrition for healthy living cohort. <span><span class="ref-journal">Clin Infect Dis. </span>2006 Mar 15;<span class="ref-vol">42</span>(6):836-42.</span> [<a href="https://pubmed.ncbi.nlm.nih.gov/16477562" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 16477562</span></a>]</div></dd></dl><dl class="bkr_refwrap"><dt>28.</dt><dd><div class="bk_ref" id="article-149535.r28">Huang JS, Wilkie SJ, Dolan S, Gallafent JH, Aliabadi N, Sullivan MP, Grinspoon S. Reduced testosterone levels in human immunodeficiency virus-infected women with weight loss and low weight. <span><span class="ref-journal">Clin Infect Dis. </span>2003 Feb 15;<span class="ref-vol">36</span>(4):499-506.</span> [<a href="https://pubmed.ncbi.nlm.nih.gov/12567309" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 12567309</span></a>]</div></dd></dl><dl class="bkr_refwrap"><dt>29.</dt><dd><div class="bk_ref" id="article-149535.r29">Grunfeld C, Feingold KR. Metabolic disturbances and wasting in the acquired immunodeficiency syndrome. <span><span class="ref-journal">N Engl J Med. </span>1992 Jul 30;<span class="ref-vol">327</span>(5):329-37.</span> [<a href="https://pubmed.ncbi.nlm.nih.gov/1620172" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 1620172</span></a>]</div></dd></dl><dl class="bkr_refwrap"><dt>30.</dt><dd><div class="bk_ref" id="article-149535.r30">Nemechek PM, Polsky B, Gottlieb MS. Treatment guidelines for HIV-associated wasting. <span><span class="ref-journal">Mayo Clin Proc. </span>2000 Apr;<span class="ref-vol">75</span>(4):386-94.</span> [<a href="https://pubmed.ncbi.nlm.nih.gov/10761494" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 10761494</span></a>]</div></dd></dl><dl class="bkr_refwrap"><dt>31.</dt><dd><div class="bk_ref" id="article-149535.r31">Wanke CA, Silva M, Knox TA, Forrester J, Speigelman D, Gorbach SL. Weight loss and wasting remain common complications in individuals infected with human immunodeficiency virus in the era of highly active antiretroviral therapy. <span><span class="ref-journal">Clin Infect Dis. </span>2000 Sep;<span class="ref-vol">31</span>(3):803-5.</span> [<a href="https://pubmed.ncbi.nlm.nih.gov/11017833" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 11017833</span></a>]</div></dd></dl><dl class="bkr_refwrap"><dt>32.</dt><dd><div class="bk_ref" id="article-149535.r32">Baril JG, Junod P, Leblanc R, Dion H, Therrien R, Laplante F, Falutz J, Côté P, Hébert MN, Lalonde R, Lapointe N, Lévesque D, Pinault L, Rouleau D, Tremblay C, Trottier B, Trottier S, Tsoukas C, Weiss K. HIV-associated lipodystrophy syndrome: A review of clinical aspects. <span><span class="ref-journal">Can J Infect Dis Med Microbiol. </span>2005 Jul;<span class="ref-vol">16</span>(4):233-43.</span> [<a href="/pmc/articles/PMC2095035/" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pmc">PMC free article<span class="bk_prnt">: PMC2095035</span></a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/18159551" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 18159551</span></a>]</div></dd></dl><dl class="bkr_refwrap"><dt>33.</dt><dd><div class="bk_ref" id="article-149535.r33">Gallant JE, Staszewski S, Pozniak AL, DeJesus E, Suleiman JM, Miller MD, Coakley DF, Lu B, Toole JJ, Cheng AK., 903 Study Group. Efficacy and safety of tenofovir DF vs stavudine in combination therapy in antiretroviral-naive patients: a 3-year randomized trial. <span><span class="ref-journal">JAMA. </span>2004 Jul 14;<span class="ref-vol">292</span>(2):191-201.</span> [<a href="https://pubmed.ncbi.nlm.nih.gov/15249568" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 15249568</span></a>]</div></dd></dl><dl class="bkr_refwrap"><dt>34.</dt><dd><div class="bk_ref" id="article-149535.r34">Podzamczer D, Ferrer E, Sanchez P, Gatell JM, Crespo M, Fisac C, Lonca M, Sanz J, Niubo J, Veloso S, Llibre JM, Barrufet P, Ribas MA, Merino E, Ribera E, Martínez-Lacasa J, Alonso C, Aranda M, Pulido F, Berenguer J, Delegido A, Pedreira JD, Lérida A, Rubio R, del Río L., ABCDE (Abacavir vs. d4T (stavudine) plus efavirenz) Study Team. Less lipoatrophy and better lipid profile with abacavir as compared to stavudine: 96-week results of a randomized study. <span><span class="ref-journal">J Acquir Immune Defic Syndr. </span>2007 Feb 01;<span class="ref-vol">44</span>(2):139-47.</span> [<a href="https://pubmed.ncbi.nlm.nih.gov/17106274" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 17106274</span></a>]</div></dd></dl><dl class="bkr_refwrap"><dt>35.</dt><dd><div class="bk_ref" id="article-149535.r35">Wohl DA, McComsey G, Tebas P, Brown TT, Glesby MJ, Reeds D, Shikuma C, Mulligan K, Dube M, Wininger D, Huang J, Revuelta M, Currier J, Swindells S, Fichtenbaum C, Basar M, Tungsiripat M, Meyer W, Weihe J, Wanke C. Current concepts in the diagnosis and management of metabolic complications of HIV infection and its therapy. <span><span class="ref-journal">Clin Infect Dis. </span>2006 Sep 01;<span class="ref-vol">43</span>(5):645-53.</span> [<a href="https://pubmed.ncbi.nlm.nih.gov/16886161" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 16886161</span></a>]</div></dd></dl><dl class="bkr_refwrap"><dt>36.</dt><dd><div class="bk_ref" id="article-149535.r36">McComsey GA, Moser C, Currier J, Ribaudo HJ, Paczuski P, Dubé MP, Kelesidis T, Rothenberg J, Stein JH, Brown TT. Body Composition Changes After Initiation of Raltegravir or Protease Inhibitors: ACTG A5260s. <span><span class="ref-journal">Clin Infect Dis. </span>2016 Apr 01;<span class="ref-vol">62</span>(7):853-62.</span> [<a href="/pmc/articles/PMC4787610/" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pmc">PMC free article<span class="bk_prnt">: PMC4787610</span></a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/26797215" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 26797215</span></a>]</div></dd></dl><dl class="bkr_refwrap"><dt>37.</dt><dd><div class="bk_ref" id="article-149535.r37">Domingo P, Gutierrez Mdel M, Gallego-Escuredo JM, Torres F, Mateo GM, Villarroya J, de los Santos I, Domingo JC, Villarroya F, Del Rio L, Estrada V, Giralt M. Effects of switching from stavudine to raltegravir on subcutaneous adipose tissue in HIV-infected patients with HIV/HAART-associated lipodystrophy syndrome (HALS). A clinical and molecular study. <span><span class="ref-journal">PLoS One. </span>2014;<span class="ref-vol">9</span>(2):e89088.</span> [<a href="/pmc/articles/PMC3935839/" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pmc">PMC free article<span class="bk_prnt">: PMC3935839</span></a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/24586518" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 24586518</span></a>]</div></dd></dl><dl class="bkr_refwrap"><dt>38.</dt><dd><div class="bk_ref" id="article-149535.r38">Shlay JC, Bartsch G, Peng G, Wang J, Grunfeld C, Gibert CL, Visnegarwala F, Raghavan SS, Xiang Y, Farrough M, Perry HE, Kotler D, El-Sadr WM. Long-term body composition and metabolic changes in antiretroviral naive persons randomized to protease inhibitor-, nonnucleoside reverse transcriptase inhibitor-, or protease inhibitor plus nonnucleoside reverse transcriptase inhibitor-based strategy. <span><span class="ref-journal">J Acquir Immune Defic Syndr. </span>2007 Apr 15;<span class="ref-vol">44</span>(5):506-17.</span> [<a href="https://pubmed.ncbi.nlm.nih.gov/17325603" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 17325603</span></a>]</div></dd></dl><dl class="bkr_refwrap"><dt>39.</dt><dd><div class="bk_ref" id="article-149535.r39">Sax PE, Kumar P. Tolerability and safety of HIV protease inhibitors in adults. <span><span class="ref-journal">J Acquir Immune Defic Syndr. </span>2004 Sep 01;<span class="ref-vol">37</span>(1):1111-24.</span> [<a href="https://pubmed.ncbi.nlm.nih.gov/15319670" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 15319670</span></a>]</div></dd></dl><dl class="bkr_refwrap"><dt>40.</dt><dd><div class="bk_ref" id="article-149535.r40">Hernandez-Romieu AC, Garg S, Rosenberg ES, Thompson-Paul AM, Skarbinski J. Is diabetes prevalence higher among HIV-infected individuals compared with the general population? Evidence from MMP and NHANES 2009-2010. <span><span class="ref-journal">BMJ Open Diabetes Res Care. </span>2017;<span class="ref-vol">5</span>(1):e000304.</span> [<a href="/pmc/articles/PMC5293823/" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pmc">PMC free article<span class="bk_prnt">: PMC5293823</span></a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/28191320" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 28191320</span></a>]</div></dd></dl><dl class="bkr_refwrap"><dt>41.</dt><dd><div class="bk_ref" id="article-149535.r41">Grunfeld C. Insulin resistance in HIV infection: drugs, host responses, or restoration to health? <span><span class="ref-journal">Top HIV Med. </span>2008 Jun-Jul;<span class="ref-vol">16</span>(2):89-93.</span> [<a href="https://pubmed.ncbi.nlm.nih.gov/18591716" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 18591716</span></a>]</div></dd></dl><dl class="bkr_refwrap"><dt>42.</dt><dd><div class="bk_ref" id="article-149535.r42">Addy CL, Gavrila A, Tsiodras S, Brodovicz K, Karchmer AW, Mantzoros CS. Hypoadiponectinemia is associated with insulin resistance, hypertriglyceridemia, and fat redistribution in human immunodeficiency virus-infected patients treated with highly active antiretroviral therapy. <span><span class="ref-journal">J Clin Endocrinol Metab. </span>2003 Feb;<span class="ref-vol">88</span>(2):627-36.</span> [<a href="https://pubmed.ncbi.nlm.nih.gov/12574192" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 12574192</span></a>]</div></dd></dl><dl class="bkr_refwrap"><dt>43.</dt><dd><div class="bk_ref" id="article-149535.r43">Tebas P. Insulin resistance and diabetes mellitus associated with antiretroviral use in HIV-infected patients: pathogenesis, prevention, and treatment options. <span><span class="ref-journal">J Acquir Immune Defic Syndr. </span>2008 Sep 01;<span class="ref-vol">49 Suppl 2</span>:S86-92.</span> [<a href="https://pubmed.ncbi.nlm.nih.gov/18725817" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 18725817</span></a>]</div></dd></dl><dl class="bkr_refwrap"><dt>44.</dt><dd><div class="bk_ref" id="article-149535.r44">White JR, Campbell RK. Dangerous and common drug interactions in patients with diabetes mellitus. <span><span class="ref-journal">Endocrinol Metab Clin North Am. </span>2000 Dec;<span class="ref-vol">29</span>(4):789-802.</span> [<a href="https://pubmed.ncbi.nlm.nih.gov/11149162" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 11149162</span></a>]</div></dd></dl><dl class="bkr_refwrap"><dt>45.</dt><dd><div class="bk_ref" id="article-149535.r45">Brown TT, Tassiopoulos K, Bosch RJ, Shikuma C, McComsey GA. Association between systemic inflammation and incident diabetes in HIV-infected patients after initiation of antiretroviral therapy. <span><span class="ref-journal">Diabetes Care. </span>2010 Oct;<span class="ref-vol">33</span>(10):2244-9.</span> [<a href="/pmc/articles/PMC2945167/" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pmc">PMC free article<span class="bk_prnt">: PMC2945167</span></a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/20664016" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 20664016</span></a>]</div></dd></dl><dl class="bkr_refwrap"><dt>46.</dt><dd><div class="bk_ref" id="article-149535.r46">Grunfeld C, Pang M, Doerrler W, Shigenaga JK, Jensen P, Feingold KR. Lipids, lipoproteins, triglyceride clearance, and cytokines in human immunodeficiency virus infection and the acquired immunodeficiency syndrome. <span><span class="ref-journal">J Clin Endocrinol Metab. </span>1992 May;<span class="ref-vol">74</span>(5):1045-52.</span> [<a href="https://pubmed.ncbi.nlm.nih.gov/1373735" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 1373735</span></a>]</div></dd></dl><dl class="bkr_refwrap"><dt>47.</dt><dd><div class="bk_ref" id="article-149535.r47">Mujawar Z, Rose H, Morrow MP, Pushkarsky T, Dubrovsky L, Mukhamedova N, Fu Y, Dart A, Orenstein JM, Bobryshev YV, Bukrinsky M, Sviridov D. Human immunodeficiency virus impairs reverse cholesterol transport from macrophages. <span><span class="ref-journal">PLoS Biol. </span>2006 Oct;<span class="ref-vol">4</span>(11):e365.</span> [<a href="/pmc/articles/PMC1629034/" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pmc">PMC free article<span class="bk_prnt">: PMC1629034</span></a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/17076584" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 17076584</span></a>]</div></dd></dl><dl class="bkr_refwrap"><dt>48.</dt><dd><div class="bk_ref" id="article-149535.r48">Shafran SD, Mashinter LD, Roberts SE. The effect of low-dose ritonavir monotherapy on fasting serum lipid concentrations. <span><span class="ref-journal">HIV Med. </span>2005 Nov;<span class="ref-vol">6</span>(6):421-5.</span> [<a href="https://pubmed.ncbi.nlm.nih.gov/16268824" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 16268824</span></a>]</div></dd></dl><dl class="bkr_refwrap"><dt>49.</dt><dd><div class="bk_ref" id="article-149535.r49">Mills AM, Nelson M, Jayaweera D, Ruxrungtham K, Cassetti I, Girard PM, Workman C, Dierynck I, Sekar V, Abeele CV, Lavreys L. Once-daily darunavir/ritonavir vs. lopinavir/ritonavir in treatment-naive, HIV-1-infected patients: 96-week analysis. <span><span class="ref-journal">AIDS. </span>2009 Aug 24;<span class="ref-vol">23</span>(13):1679-88.</span> [<a href="https://pubmed.ncbi.nlm.nih.gov/19487905" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 19487905</span></a>]</div></dd></dl><dl class="bkr_refwrap"><dt>50.</dt><dd><div class="bk_ref" id="article-149535.r50">Carey D, Amin J, Boyd M, Petoumenos K, Emery S. Lipid profiles in HIV-infected adults receiving atazanavir and atazanavir/ritonavir: systematic review and meta-analysis of randomized controlled trials. <span><span class="ref-journal">J Antimicrob Chemother. </span>2010 Sep;<span class="ref-vol">65</span>(9):1878-88.</span> [<a href="https://pubmed.ncbi.nlm.nih.gov/20554568" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 20554568</span></a>]</div></dd></dl><dl class="bkr_refwrap"><dt>51.</dt><dd><div class="bk_ref" id="article-149535.r51">Gatell J, Salmon-Ceron D, Lazzarin A, Van Wijngaerden E, Antunes F, Leen C, Horban A, Wirtz V, Odeshoo L, Van den Dungen M, Gruber C, Ledesma E., SWAN Study Group. Efficacy and safety of atazanavir-based highly active antiretroviral therapy in patients with virologic suppression switched from a stable, boosted or unboosted protease inhibitor treatment regimen: the SWAN Study (AI424-097) 48-week results. <span><span class="ref-journal">Clin Infect Dis. </span>2007 Jun 01;<span class="ref-vol">44</span>(11):1484-92.</span> [<a href="https://pubmed.ncbi.nlm.nih.gov/17479947" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 17479947</span></a>]</div></dd></dl><dl class="bkr_refwrap"><dt>52.</dt><dd><div class="bk_ref" id="article-149535.r52">Molina JM, Cahn P, Grinsztejn B, Lazzarin A, Mills A, Saag M, Supparatpinyo K, Walmsley S, Crauwels H, Rimsky LT, Vanveggel S, Boven K., ECHO study group. Rilpivirine versus efavirenz with tenofovir and emtricitabine in treatment-naive adults infected with HIV-1 (ECHO): a phase 3 randomised double-blind active-controlled trial. <span><span class="ref-journal">Lancet. </span>2011 Jul 16;<span class="ref-vol">378</span>(9787):238-46.</span> [<a href="https://pubmed.ncbi.nlm.nih.gov/21763936" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 21763936</span></a>]</div></dd></dl><dl class="bkr_refwrap"><dt>53.</dt><dd><div class="bk_ref" id="article-149535.r53">Lazzarin A, Campbell T, Clotet B, Johnson M, Katlama C, Moll A, Towner W, Trottier B, Peeters M, Vingerhoets J, de Smedt G, Baeten B, Beets G, Sinha R, Woodfall B., DUET-2 study group. Efficacy and safety of TMC125 (etravirine) in treatment-experienced HIV-1-infected patients in DUET-2: 24-week results from a randomised, double-blind, placebo-controlled trial. <span><span class="ref-journal">Lancet. </span>2007 Jul 07;<span class="ref-vol">370</span>(9581):39-48.</span> [<a href="https://pubmed.ncbi.nlm.nih.gov/17617271" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 17617271</span></a>]</div></dd></dl><dl class="bkr_refwrap"><dt>54.</dt><dd><div class="bk_ref" id="article-149535.r54">Crane HM, Grunfeld C, Willig JH, Mugavero MJ, Van Rompaey S, Moore R, Rodriguez B, Feldman BJ, Lederman MM, Saag MS, Kitahata MM. Impact of NRTIs on lipid levels among a large HIV-infected cohort initiating antiretroviral therapy in clinical care. <span><span class="ref-journal">AIDS. </span>2011 Jan 14;<span class="ref-vol">25</span>(2):185-95.</span> [<a href="/pmc/articles/PMC6027746/" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pmc">PMC free article<span class="bk_prnt">: PMC6027746</span></a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/21150555" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 21150555</span></a>]</div></dd></dl><dl class="bkr_refwrap"><dt>55.</dt><dd><div class="bk_ref" id="article-149535.r55">Mills A, Crofoot G, McDonald C, Shalit P, Flamm JA, Gathe J, Scribner A, Shamblaw D, Saag M, Cao H, Martin H, Das M, Thomas A, Liu HC, Yan M, Callebaut C, Custodio J, Cheng A, McCallister S. Tenofovir Alafenamide Versus Tenofovir Disoproxil Fumarate in the First Protease Inhibitor-Based Single-Tablet Regimen for Initial HIV-1 Therapy: A Randomized Phase 2 Study. <span><span class="ref-journal">J Acquir Immune Defic Syndr. </span>2015 Aug 01;<span class="ref-vol">69</span>(4):439-45.</span> [<a href="https://pubmed.ncbi.nlm.nih.gov/25867913" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 25867913</span></a>]</div></dd></dl><dl class="bkr_refwrap"><dt>56.</dt><dd><div class="bk_ref" id="article-149535.r56">Ofotokun I, Na LH, Landovitz RJ, Ribaudo HJ, McComsey GA, Godfrey C, Aweeka F, Cohn SE, Sagar M, Kuritzkes DR, Brown TT, Patterson KB, Para MF, Leavitt RY, Villasis-Keever A, Baugh BP, Lennox JL, Currier JS., AIDS Clinical Trials Group (ACTG) A5257 Team. Comparison of the metabolic effects of ritonavir-boosted darunavir or atazanavir versus raltegravir, and the impact of ritonavir plasma exposure: ACTG 5257. <span><span class="ref-journal">Clin Infect Dis. </span>2015 Jun 15;<span class="ref-vol">60</span>(12):1842-51.</span> [<a href="/pmc/articles/PMC4660025/" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pmc">PMC free article<span class="bk_prnt">: PMC4660025</span></a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/25767256" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 25767256</span></a>]</div></dd></dl><dl class="bkr_refwrap"><dt>57.</dt><dd><div class="bk_ref" id="article-149535.r57">De Vincentis S, Rochira V. Update on acquired hypogonadism in men living with HIV: pathogenesis, clinic, and treatment. <span><span class="ref-journal">Front Endocrinol (Lausanne). </span>2023;<span class="ref-vol">14</span>:1201696.</span> [<a href="/pmc/articles/PMC10338827/" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pmc">PMC free article<span class="bk_prnt">: PMC10338827</span></a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/37455928" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 37455928</span></a>]</div></dd></dl><dl class="bkr_refwrap"><dt>58.</dt><dd><div class="bk_ref" id="article-149535.r58">Sinha U, Sengupta N, Mukhopadhyay P, Roy KS. Human immunodeficiency virus endocrinopathy. <span><span class="ref-journal">Indian J Endocrinol Metab. </span>2011 Oct;<span class="ref-vol">15</span>(4):251-60.</span> [<a href="/pmc/articles/PMC3193773/" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pmc">PMC free article<span class="bk_prnt">: PMC3193773</span></a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/22028995" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 22028995</span></a>]</div></dd></dl><dl class="bkr_refwrap"><dt>59.</dt><dd><div class="bk_ref" id="article-149535.r59">Dolan SE, Grinspoon S. Androgen deficiency and the role of testosterone administration in HIV-infected women. <span><span class="ref-journal">J Acquir Immune Defic Syndr. </span>2005 Mar;<span class="ref-vol">38 Suppl 1</span>:S48-9.</span> [<a href="https://pubmed.ncbi.nlm.nih.gov/15867625" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 15867625</span></a>]</div></dd></dl><dl class="bkr_refwrap"><dt>60.</dt><dd><div class="bk_ref" id="article-149535.r60">Siddiqui J, Samuel SK, Hayward B, Wirka KA, Deering KL, Harshaw Q, Phillips A, Harbour M. HIV-associated wasting prevalence in the era of modern antiretroviral therapy. <span><span class="ref-journal">AIDS. </span>2022 Jan 01;<span class="ref-vol">36</span>(1):127-135.</span> [<a href="/pmc/articles/PMC8654247/" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pmc">PMC free article<span class="bk_prnt">: PMC8654247</span></a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/34628440" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 34628440</span></a>]</div></dd></dl><dl class="bkr_refwrap"><dt>61.</dt><dd><div class="bk_ref" id="article-149535.r61">Jacobson DL, Knox T, Spiegelman D, Skinner S, Gorbach S, Wanke C. Prevalence of, evolution of, and risk factors for fat atrophy and fat deposition in a cohort of HIV-infected men and women. <span><span class="ref-journal">Clin Infect Dis. </span>2005 Jun 15;<span class="ref-vol">40</span>(12):1837-45.</span> [<a href="https://pubmed.ncbi.nlm.nih.gov/15909274" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 15909274</span></a>]</div></dd></dl><dl class="bkr_refwrap"><dt>62.</dt><dd><div class="bk_ref" id="article-149535.r62">Mothe B, Perez I, Domingo P, Podzamczer D, Ribera E, Curran A, Viladés C, Vidal F, Dalmau D, Pedrol E, Negredo E, Moltó J, Paredes R, Perez-Alvarez N, Gatell JM, Clotet B. HIV-1 infection in subjects older than 70: a multicenter cross-sectional assessment in Catalonia, Spain. <span><span class="ref-journal">Curr HIV Res. </span>2009 Nov;<span class="ref-vol">7</span>(6):597-600.</span> [<a href="https://pubmed.ncbi.nlm.nih.gov/19929794" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 19929794</span></a>]</div></dd></dl><dl class="bkr_refwrap"><dt>63.</dt><dd><div class="bk_ref" id="article-149535.r63">Heymann WR. Cutaneous manifestations of thyroid disease. <span><span class="ref-journal">J Am Acad Dermatol. </span>1992 Jun;<span class="ref-vol">26</span>(6):885-902.</span> [<a href="https://pubmed.ncbi.nlm.nih.gov/1607406" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 1607406</span></a>]</div></dd></dl><dl class="bkr_refwrap"><dt>64.</dt><dd><div class="bk_ref" id="article-149535.r64">Bilezikian JP, Loeb JN. The influence of hyperthyroidism and hypothyroidism on alpha- and beta-adrenergic receptor systems and adrenergic responsiveness. <span><span class="ref-journal">Endocr Rev. </span>1983 Fall;<span class="ref-vol">4</span>(4):378-88.</span> [<a href="https://pubmed.ncbi.nlm.nih.gov/6317368" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 6317368</span></a>]</div></dd></dl><dl class="bkr_refwrap"><dt>65.</dt><dd><div class="bk_ref" id="article-149535.r65">Lee MH, Chin YH, Ng CH, Nistala KRY, Ow ZGW, Sundar G, Yang SP, Khoo CM. Risk Factors of Thyroid Eye Disease. <span><span class="ref-journal">Endocr Pract. </span>2021 Mar;<span class="ref-vol">27</span>(3):245-253.</span> [<a href="https://pubmed.ncbi.nlm.nih.gov/33655885" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 33655885</span></a>]</div></dd></dl><dl class="bkr_refwrap"><dt>66.</dt><dd><div class="bk_ref" id="article-149535.r66">Rushworth RL, Torpy DJ, Falhammar H. Adrenal Crisis. <span><span class="ref-journal">N Engl J Med. </span>2019 Aug 29;<span class="ref-vol">381</span>(9):852-861.</span> [<a href="https://pubmed.ncbi.nlm.nih.gov/31461595" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 31461595</span></a>]</div></dd></dl><dl class="bkr_refwrap"><dt>67.</dt><dd><div class="bk_ref" id="article-149535.r67">Husebye ES, Pearce SH, Krone NP, Kämpe O. Adrenal insufficiency. <span><span class="ref-journal">Lancet. </span>2021 Feb 13;<span class="ref-vol">397</span>(10274):613-629.</span> [<a href="https://pubmed.ncbi.nlm.nih.gov/33484633" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 33484633</span></a>]</div></dd></dl><dl class="bkr_refwrap"><dt>68.</dt><dd><div class="bk_ref" id="article-149535.r68">Reincke M, Fleseriu M. Cushing Syndrome: A Review. <span><span class="ref-journal">JAMA. </span>2023 Jul 11;<span class="ref-vol">330</span>(2):170-181.</span> [<a href="https://pubmed.ncbi.nlm.nih.gov/37432427" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 37432427</span></a>]</div></dd></dl><dl class="bkr_refwrap"><dt>69.</dt><dd><div class="bk_ref" id="article-149535.r69">Svedbom A, Hernlund E, Ivergård M, Compston J, Cooper C, Stenmark J, McCloskey EV, Jönsson B, Kanis JA., EU Review Panel of IOF. Osteoporosis in the European Union: a compendium of country-specific reports. <span><span class="ref-journal">Arch Osteoporos. </span>2013;<span class="ref-vol">8</span>(1):137.</span> [<a href="/pmc/articles/PMC3880492/" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pmc">PMC free article<span class="bk_prnt">: PMC3880492</span></a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/24113838" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 24113838</span></a>]</div></dd></dl><dl class="bkr_refwrap"><dt>70.</dt><dd><div class="bk_ref" id="article-149535.r70">Bhasin S, Cunningham GR, Hayes FJ, Matsumoto AM, Snyder PJ, Swerdloff RS, Montori VM., Task Force, Endocrine Society. Testosterone therapy in men with androgen deficiency syndromes: an Endocrine Society clinical practice guideline. <span><span class="ref-journal">J Clin Endocrinol Metab. </span>2010 Jun;<span class="ref-vol">95</span>(6):2536-59.</span> [<a href="https://pubmed.ncbi.nlm.nih.gov/20525905" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 20525905</span></a>]</div></dd></dl><dl class="bkr_refwrap"><dt>71.</dt><dd><div class="bk_ref" id="article-149535.r71">Rawla P, Sunkara T, Thandra KC, Gaduputi V. Hypertriglyceridemia-induced pancreatitis: updated review of current treatment and preventive strategies. <span><span class="ref-journal">Clin J Gastroenterol. </span>2018 Dec;<span class="ref-vol">11</span>(6):441-448.</span> [<a href="https://pubmed.ncbi.nlm.nih.gov/29923163" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 29923163</span></a>]</div></dd></dl><dl class="bkr_refwrap"><dt>72.</dt><dd><div class="bk_ref" id="article-149535.r72">Garber JR, Cobin RH, Gharib H, Hennessey JV, Klein I, Mechanick JI, Pessah-Pollack R, Singer PA, Woeber KA., American Association of Clinical Endocrinologists and American Thyroid Association Taskforce on Hypothyroidism in Adults. Clinical practice guidelines for hypothyroidism in adults: cosponsored by the American Association of Clinical Endocrinologists and the American Thyroid Association. <span><span class="ref-journal">Endocr Pract. </span>2012 Nov-Dec;<span class="ref-vol">18</span>(6):988-1028.</span> [<a href="https://pubmed.ncbi.nlm.nih.gov/23246686" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 23246686</span></a>]</div></dd></dl><dl class="bkr_refwrap"><dt>73.</dt><dd><div class="bk_ref" id="article-149535.r73">Deutschbein T, Unger N, Mann K, Petersenn S. Diagnosis of secondary adrenal insufficiency: unstimulated early morning cortisol in saliva and serum in comparison with the insulin tolerance test. <span><span class="ref-journal">Horm Metab Res. </span>2009 Nov;<span class="ref-vol">41</span>(11):834-9.</span> [<a href="https://pubmed.ncbi.nlm.nih.gov/19585406" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 19585406</span></a>]</div></dd></dl><dl class="bkr_refwrap"><dt>74.</dt><dd><div class="bk_ref" id="article-149535.r74">Zha L, Li J, Krishnan SM, Brennan MR, Zhang YV, Povse P, Kerlin R, Shively K, Oleksik F, Williams J, Sykes E, Sun Q. New Diagnostic Cutoffs for Adrenal Insufficiency After Cosyntropin Stimulation Using Abbott Architect Cortisol Immunoassay. <span><span class="ref-journal">Endocr Pract. </span>2022 Jul;<span class="ref-vol">28</span>(7):684-689.</span> [<a href="https://pubmed.ncbi.nlm.nih.gov/35487459" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 35487459</span></a>]</div></dd></dl><dl class="bkr_refwrap"><dt>75.</dt><dd><div class="bk_ref" id="article-149535.r75">Aberg JA, Gallant JE, Ghanem KG, Emmanuel P, Zingman BS, Horberg MA., Infectious Diseases Society of America. Primary care guidelines for the management of persons infected with HIV: 2013 update by the HIV medicine association of the Infectious Diseases Society of America. <span><span class="ref-journal">Clin Infect Dis. </span>2014 Jan;<span class="ref-vol">58</span>(1):e1-34.</span> [<a href="https://pubmed.ncbi.nlm.nih.gov/24235263" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 24235263</span></a>]</div></dd></dl><dl class="bkr_refwrap"><dt>76.</dt><dd><div class="bk_ref" id="article-149535.r76">Kim PS, Woods C, Georgoff P, Crum D, Rosenberg A, Smith M, Hadigan C. A1C underestimates glycemia in HIV infection. <span><span class="ref-journal">Diabetes Care. </span>2009 Sep;<span class="ref-vol">32</span>(9):1591-3.</span> [<a href="/pmc/articles/PMC2732167/" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pmc">PMC free article<span class="bk_prnt">: PMC2732167</span></a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/19502538" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 19502538</span></a>]</div></dd></dl><dl class="bkr_refwrap"><dt>77.</dt><dd><div class="bk_ref" id="article-149535.r77">Kahaly GJ. Management of Graves Thyroidal and Extrathyroidal Disease: An Update. <span><span class="ref-journal">J Clin Endocrinol Metab. </span>2020 Dec 01;<span class="ref-vol">105</span>(12):3704-20.</span> [<a href="/pmc/articles/PMC7543578/" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pmc">PMC free article<span class="bk_prnt">: PMC7543578</span></a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/32929476" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 32929476</span></a>]</div></dd></dl><dl class="bkr_refwrap"><dt>78.</dt><dd><div class="bk_ref" id="article-149535.r78">Falutz J. Growth hormone and HIV infection: contribution to disease manifestations and clinical implications. <span><span class="ref-journal">Best Pract Res Clin Endocrinol Metab. </span>2011 Jun;<span class="ref-vol">25</span>(3):517-29.</span> [<a href="https://pubmed.ncbi.nlm.nih.gov/21663844" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 21663844</span></a>]</div></dd></dl><dl class="bkr_refwrap"><dt>79.</dt><dd><div class="bk_ref" id="article-149535.r79">Grinspoon S, Gelato M. Editorial: The rational use of growth hormone in HIV-infected patients. <span><span class="ref-journal">J Clin Endocrinol Metab. </span>2001 Aug;<span class="ref-vol">86</span>(8):3478-9.</span> [<a href="https://pubmed.ncbi.nlm.nih.gov/11502766" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 11502766</span></a>]</div></dd></dl><dl class="bkr_refwrap"><dt>80.</dt><dd><div class="bk_ref" id="article-149535.r80">Engelson ES, Glesby MJ, Mendez D, Albu JB, Wang J, Heymsfield SB, Kotler DP. Effect of recombinant human growth hormone in the treatment of visceral fat accumulation in HIV infection. <span><span class="ref-journal">J Acquir Immune Defic Syndr. </span>2002 Aug 01;<span class="ref-vol">30</span>(4):379-91.</span> [<a href="https://pubmed.ncbi.nlm.nih.gov/12138344" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 12138344</span></a>]</div></dd></dl><dl class="bkr_refwrap"><dt>81.</dt><dd><div class="bk_ref" id="article-149535.r81">Schambelan M, Mulligan K, Grunfeld C, Daar ES, LaMarca A, Kotler DP, Wang J, Bozzette SA, Breitmeyer JB. Recombinant human growth hormone in patients with HIV-associated wasting. A randomized, placebo-controlled trial. Serostim Study Group. <span><span class="ref-journal">Ann Intern Med. </span>1996 Dec 01;<span class="ref-vol">125</span>(11):873-82.</span> [<a href="https://pubmed.ncbi.nlm.nih.gov/8967667" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 8967667</span></a>]</div></dd></dl><dl class="bkr_refwrap"><dt>82.</dt><dd><div class="bk_ref" id="article-149535.r82">Moyle G, Sutinen J. Managing HIV lipoatrophy. <span><span class="ref-journal">Lancet. </span>2004 Feb 07;<span class="ref-vol">363</span>(9407):412-4.</span> [<a href="https://pubmed.ncbi.nlm.nih.gov/14962517" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 14962517</span></a>]</div></dd></dl><dl class="bkr_refwrap"><dt>83.</dt><dd><div class="bk_ref" id="article-149535.r83">Martínez E, Arnaiz JA, Podzamczer D, Dalmau D, Ribera E, Domingo P, Knobel H, Riera M, Pedrol E, Force L, Llibre JM, Segura F, Richart C, Cortés C, Javaloyas M, Aranda M, Cruceta A, de Lazzari E, Gatell JM., Nevirapine, Efavirenz, and Abacavir (NEFA) Study Team. Substitution of nevirapine, efavirenz, or abacavir for protease inhibitors in patients with human immunodeficiency virus infection. <span><span class="ref-journal">N Engl J Med. </span>2003 Sep 11;<span class="ref-vol">349</span>(11):1036-46.</span> [<a href="https://pubmed.ncbi.nlm.nih.gov/12968087" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 12968087</span></a>]</div></dd></dl><dl class="bkr_refwrap"><dt>84.</dt><dd><div class="bk_ref" id="article-149535.r84">Carr A, Workman C, Smith DE, Hoy J, Hudson J, Doong N, Martin A, Amin J, Freund J, Law M, Cooper DA., Mitochondrial Toxicity (MITOX) Study Group. Abacavir substitution for nucleoside analogs in patients with HIV lipoatrophy: a randomized trial. <span><span class="ref-journal">JAMA. </span>2002 Jul 10;<span class="ref-vol">288</span>(2):207-15.</span> [<a href="https://pubmed.ncbi.nlm.nih.gov/12095385" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 12095385</span></a>]</div></dd></dl><dl class="bkr_refwrap"><dt>85.</dt><dd><div class="bk_ref" id="article-149535.r85">Arioglu E, Duncan-Morin J, Sebring N, Rother KI, Gottlieb N, Lieberman J, Herion D, Kleiner DE, Reynolds J, Premkumar A, Sumner AE, Hoofnagle J, Reitman ML, Taylor SI. Efficacy and safety of troglitazone in the treatment of lipodystrophy syndromes. <span><span class="ref-journal">Ann Intern Med. </span>2000 Aug 15;<span class="ref-vol">133</span>(4):263-74.</span> [<a href="https://pubmed.ncbi.nlm.nih.gov/10929166" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 10929166</span></a>]</div></dd></dl><dl class="bkr_refwrap"><dt>86.</dt><dd><div class="bk_ref" id="article-149535.r86">Sivakumar T, Mechanic O, Fehmie DA, Paul B. Growth hormone axis treatments for HIV-associated lipodystrophy: a systematic review of placebo-controlled trials. <span><span class="ref-journal">HIV Med. </span>2011 Sep;<span class="ref-vol">12</span>(8):453-62.</span> [<a href="https://pubmed.ncbi.nlm.nih.gov/21265979" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 21265979</span></a>]</div></dd></dl><dl class="bkr_refwrap"><dt>87.</dt><dd><div class="bk_ref" id="article-149535.r87">Falutz J, Potvin D, Mamputu JC, Assaad H, Zoltowska M, Michaud SE, Berger D, Somero M, Moyle G, Brown S, Martorell C, Turner R, Grinspoon S. Effects of tesamorelin, a growth hormone-releasing factor, in HIV-infected patients with abdominal fat accumulation: a randomized placebo-controlled trial with a safety extension. <span><span class="ref-journal">J Acquir Immune Defic Syndr. </span>2010 Mar;<span class="ref-vol">53</span>(3):311-22.</span> [<a href="https://pubmed.ncbi.nlm.nih.gov/20101189" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 20101189</span></a>]</div></dd></dl><dl class="bkr_refwrap"><dt>88.</dt><dd><div class="bk_ref" id="article-149535.r88">Falutz J, Allas S, Mamputu JC, Potvin D, Kotler D, Somero M, Berger D, Brown S, Richmond G, Fessel J, Turner R, Grinspoon S. Long-term safety and effects of tesamorelin, a growth hormone-releasing factor analogue, in HIV patients with abdominal fat accumulation. <span><span class="ref-journal">AIDS. </span>2008 Sep 12;<span class="ref-vol">22</span>(14):1719-28.</span> [<a href="https://pubmed.ncbi.nlm.nih.gov/18690162" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 18690162</span></a>]</div></dd></dl><dl class="bkr_refwrap"><dt>89.</dt><dd><div class="bk_ref" id="article-149535.r89">ElSayed NA, Aleppo G, Aroda VR, Bannuru RR, Brown FM, Bruemmer D, Collins BS, Hilliard ME, Isaacs D, Johnson EL, Kahan S, Khunti K, Leon J, Lyons SK, Perry ML, Prahalad P, Pratley RE, Seley JJ, Stanton RC, Gabbay RA, on behalf of the American Diabetes Association 9. Pharmacologic Approaches to Glycemic Treatment: Standards of Care in Diabetes-2023. <span><span class="ref-journal">Diabetes Care. </span>2023 Jan 01;<span class="ref-vol">46</span>(Suppl 1):S140-S157.</span> [<a href="/pmc/articles/PMC9810476/" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pmc">PMC free article<span class="bk_prnt">: PMC9810476</span></a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/36507650" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 36507650</span></a>]</div></dd></dl><dl class="bkr_refwrap"><dt>90.</dt><dd><div class="bk_ref" id="article-149535.r90">ElSayed NA, Aleppo G, Aroda VR, Bannuru RR, Brown FM, Bruemmer D, Collins BS, Hilliard ME, Isaacs D, Johnson EL, Kahan S, Khunti K, Leon J, Lyons SK, Perry ML, Prahalad P, Pratley RE, Seley JJ, Stanton RC, Gabbay RA, on behalf of the American Diabetes Association 6. Glycemic Targets: Standards of Care in Diabetes-2023. <span><span class="ref-journal">Diabetes Care. </span>2023 Jan 01;<span class="ref-vol">46</span>(Suppl 1):S97-S110.</span> [<a href="/pmc/articles/PMC9810469/" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pmc">PMC free article<span class="bk_prnt">: PMC9810469</span></a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/36507646" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 36507646</span></a>]</div></dd></dl><dl class="bkr_refwrap"><dt>91.</dt><dd><div class="bk_ref" id="article-149535.r91">ElSayed NA, Aleppo G, Aroda VR, Bannuru RR, Brown FM, Bruemmer D, Collins BS, Hilliard ME, Isaacs D, Johnson EL, Kahan S, Khunti K, Leon J, Lyons SK, Perry ML, Prahalad P, Pratley RE, Seley JJ, Stanton RC, Gabbay RA, on behalf of the American Diabetes Association 8. Obesity and Weight Management for the Prevention and Treatment of Type 2 Diabetes: Standards of Care in Diabetes-2023. <span><span class="ref-journal">Diabetes Care. </span>2023 Jan 01;<span class="ref-vol">46</span>(Suppl 1):S128-S139.</span> [<a href="/pmc/articles/PMC9810466/" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pmc">PMC free article<span class="bk_prnt">: PMC9810466</span></a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/36507637" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 36507637</span></a>]</div></dd></dl><dl class="bkr_refwrap"><dt>92.</dt><dd><div class="bk_ref" id="article-149535.r92">Maggi P, Di Biagio A, Rusconi S, Cicalini S, D'Abbraccio M, d'Ettorre G, Martinelli C, Nunnari G, Sighinolfi L, Spagnuolo V, Squillace N. Cardiovascular risk and dyslipidemia among persons living with HIV: a review. <span><span class="ref-journal">BMC Infect Dis. </span>2017 Aug 09;<span class="ref-vol">17</span>(1):551.</span> [<a href="/pmc/articles/PMC5550957/" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pmc">PMC free article<span class="bk_prnt">: PMC5550957</span></a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/28793863" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 28793863</span></a>]</div></dd></dl><dl class="bkr_refwrap"><dt>93.</dt><dd><div class="bk_ref" id="article-149535.r93">Aberg JA, Sponseller CA, Ward DJ, Kryzhanovski VA, Campbell SE, Thompson MA. Pitavastatin versus pravastatin in adults with HIV-1 infection and dyslipidaemia (INTREPID): 12 week and 52 week results of a phase 4, multicentre, randomised, double-blind, superiority trial. <span><span class="ref-journal">Lancet HIV. </span>2017 Jul;<span class="ref-vol">4</span>(7):e284-e294.</span> [<a href="https://pubmed.ncbi.nlm.nih.gov/28416195" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 28416195</span></a>]</div></dd></dl><dl class="bkr_refwrap"><dt>94.</dt><dd><div class="bk_ref" id="article-149535.r94">Grinspoon SK, Fitch KV, Zanni MV, Fichtenbaum CJ, Umbleja T, Aberg JA, Overton ET, Malvestutto CD, Bloomfield GS, Currier JS, Martinez E, Roa JC, Diggs MR, Fulda ES, Paradis K, Wiviott SD, Foldyna B, Looby SE, Desvigne-Nickens P, Alston-Smith B, Leon-Cruz J, McCallum S, Hoffmann U, Lu MT, Ribaudo HJ, Douglas PS., REPRIEVE Investigators. Pitavastatin to Prevent Cardiovascular Disease in HIV Infection. <span><span class="ref-journal">N Engl J Med. </span>2023 Aug 24;<span class="ref-vol">389</span>(8):687-699.</span> [<a href="/pmc/articles/PMC10564556/" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pmc">PMC free article<span class="bk_prnt">: PMC10564556</span></a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/37486775" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 37486775</span></a>]</div></dd></dl><dl class="bkr_refwrap"><dt>95.</dt><dd><div class="bk_ref" id="article-149535.r95">Dubé MP, Stein JH, Aberg JA, Fichtenbaum CJ, Gerber JG, Tashima KT, Henry WK, Currier JS, Sprecher D, Glesby MJ., Adult AIDS Clinical Trials Group Cardiovascular Subcommittee. HIV Medical Association of the Infectious Disease Society of America. Guidelines for the evaluation and management of dyslipidemia in human immunodeficiency virus (HIV)-infected adults receiving antiretroviral therapy: recommendations of the HIV Medical Association of the Infectious Disease Society of America and the Adult AIDS Clinical Trials Group. <span><span class="ref-journal">Clin Infect Dis. </span>2003 Sep 01;<span class="ref-vol">37</span>(5):613-27.</span> [<a href="https://pubmed.ncbi.nlm.nih.gov/12942391" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 12942391</span></a>]</div></dd></dl><dl class="bkr_refwrap"><dt>96.</dt><dd><div class="bk_ref" id="article-149535.r96">Das Pradhan A, Glynn RJ, Fruchart JC, MacFadyen JG, Zaharris ES, Everett BM, Campbell SE, Oshima R, Amarenco P, Blom DJ, Brinton EA, Eckel RH, Elam MB, Felicio JS, Ginsberg HN, Goudev A, Ishibashi S, Joseph J, Kodama T, Koenig W, Leiter LA, Lorenzatti AJ, Mankovsky B, Marx N, Nordestgaard BG, Páll D, Ray KK, Santos RD, Soran H, Susekov A, Tendera M, Yokote K, Paynter NP, Buring JE, Libby P, Ridker PM., PROMINENT Investigators. Triglyceride Lowering with Pemafibrate to Reduce Cardiovascular Risk. <span><span class="ref-journal">N Engl J Med. </span>2022 Nov 24;<span class="ref-vol">387</span>(21):1923-1934.</span> [<a href="https://pubmed.ncbi.nlm.nih.gov/36342113" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 36342113</span></a>]</div></dd></dl><dl class="bkr_refwrap"><dt>97.</dt><dd><div class="bk_ref" id="article-149535.r97">Verma S, Bhatt DL, Steg PG, Miller M, Brinton EA, Jacobson TA, Dhingra NK, Ketchum SB, Juliano RA, Jiao L, Doyle RT, Granowitz C, Gibson CM, Pinto D, Giugliano RP, Budoff MJ, Mason RP, Tardif JC, Ballantyne CM., REDUCE-IT Investigators. Icosapent Ethyl Reduces Ischemic Events in Patients With a History of Previous Coronary Artery Bypass Grafting: REDUCE-IT CABG. <span><span class="ref-journal">Circulation. </span>2021 Dec 07;<span class="ref-vol">144</span>(23):1845-1855.</span> [<a href="https://pubmed.ncbi.nlm.nih.gov/34710343" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 34710343</span></a>]</div></dd></dl><dl class="bkr_refwrap"><dt>98.</dt><dd><div class="bk_ref" id="article-149535.r98">Ross DS, Burch HB, Cooper DS, Greenlee MC, Laurberg P, Maia AL, Rivkees SA, Samuels M, Sosa JA, Stan MN, Walter MA. 2016 American Thyroid Association Guidelines for Diagnosis and Management of Hyperthyroidism and Other Causes of Thyrotoxicosis. <span><span class="ref-journal">Thyroid. </span>2016 Oct;<span class="ref-vol">26</span>(10):1343-1421.</span> [<a href="https://pubmed.ncbi.nlm.nih.gov/27521067" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 27521067</span></a>]</div></dd></dl><dl class="bkr_refwrap"><dt>99.</dt><dd><div class="bk_ref" id="article-149535.r99">Eastell R, Rosen CJ, Black DM, Cheung AM, Murad MH, Shoback D. Pharmacological Management of Osteoporosis in Postmenopausal Women: An Endocrine Society* Clinical Practice Guideline. <span><span class="ref-journal">J Clin Endocrinol Metab. </span>2019 May 01;<span class="ref-vol">104</span>(5):1595-1622.</span> [<a href="https://pubmed.ncbi.nlm.nih.gov/30907953" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 30907953</span></a>]</div></dd></dl><dl class="bkr_refwrap"><dt>100.</dt><dd><div class="bk_ref" id="article-149535.r100">Shoback D, Rosen CJ, Black DM, Cheung AM, Murad MH, Eastell R. Pharmacological Management of Osteoporosis in Postmenopausal Women: An Endocrine Society Guideline Update. <span><span class="ref-journal">J Clin Endocrinol Metab. </span>2020 Mar 01;<span class="ref-vol">105</span>(3)</span> [<a href="https://pubmed.ncbi.nlm.nih.gov/32068863" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 32068863</span></a>]</div></dd></dl><dl class="bkr_refwrap"><dt>101.</dt><dd><div class="bk_ref" id="article-149535.r101">Molitch ME, Clemmons DR, Malozowski S, Merriam GR, Vance ML., Endocrine Society. Evaluation and treatment of adult growth hormone deficiency: an Endocrine Society clinical practice guideline. <span><span class="ref-journal">J Clin Endocrinol Metab. </span>2011 Jun;<span class="ref-vol">96</span>(6):1587-609.</span> [<a href="https://pubmed.ncbi.nlm.nih.gov/21602453" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 21602453</span></a>]</div></dd></dl><dl class="bkr_refwrap"><dt>102.</dt><dd><div class="bk_ref" id="article-149535.r102">American Diabetes Association. 2. Classification and Diagnosis of Diabetes: <em>Standards of Medical Care in Diabetes-2021</em>. <span><span class="ref-journal">Diabetes Care. </span>2021 Jan;<span class="ref-vol">44</span>(Suppl 1):S15-S33.</span> [<a href="https://pubmed.ncbi.nlm.nih.gov/33298413" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 33298413</span></a>]</div></dd></dl><dl class="bkr_refwrap"><dt>103.</dt><dd><div class="bk_ref" id="article-149535.r103">Vodnala D, Rubenfire M, Brook RD. Secondary causes of dyslipidemia. <span><span class="ref-journal">Am J Cardiol. </span>2012 Sep 15;<span class="ref-vol">110</span>(6):823-5.</span> [<a href="https://pubmed.ncbi.nlm.nih.gov/22658245" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 22658245</span></a>]</div></dd></dl><dl class="bkr_refwrap"><dt>104.</dt><dd><div class="bk_ref" id="article-149535.r104">Snyder PJ, Biller BM, Zagar A, Jackson I, Arafah BM, Nippoldt TB, Cook DM, Mooradian AD, Kwan A, Scism-Bacon J, Chipman JJ, Hartman ML. Effect of growth hormone replacement on BMD in adult-onset growth hormone deficiency. <span><span class="ref-journal">J Bone Miner Res. </span>2007 May;<span class="ref-vol">22</span>(5):762-70.</span> [<a href="https://pubmed.ncbi.nlm.nih.gov/17280527" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 17280527</span></a>]</div></dd></dl><dl class="bkr_refwrap"><dt>105.</dt><dd><div class="bk_ref" id="article-149535.r105">Maison P, Chanson P. Cardiac effects of growth hormone in adults with growth hormone deficiency: a meta-analysis. <span><span class="ref-journal">Circulation. </span>2003 Nov 25;<span class="ref-vol">108</span>(21):2648-52.</span> [<a href="https://pubmed.ncbi.nlm.nih.gov/14623813" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 14623813</span></a>]</div></dd></dl><dl class="bkr_refwrap"><dt>106.</dt><dd><div class="bk_ref" id="article-149535.r106">Johannsson G, Ragnarsson O. Growth hormone deficiency in adults with hypopituitarism-What are the risks and can they be eliminated by therapy? <span><span class="ref-journal">J Intern Med. </span>2021 Dec;<span class="ref-vol">290</span>(6):1180-1193.</span> [<a href="https://pubmed.ncbi.nlm.nih.gov/34605087" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 34605087</span></a>]</div></dd></dl><dl class="bkr_refwrap"><dt>107.</dt><dd><div class="bk_ref" id="article-149535.r107">van Bunderen CC, Olsson DS. Growth hormone deficiency and replacement therapy in adults: Impact on survival. <span><span class="ref-journal">Rev Endocr Metab Disord. </span>2021 Mar;<span class="ref-vol">22</span>(1):125-133.</span> [<a href="/pmc/articles/PMC7979620/" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pmc">PMC free article<span class="bk_prnt">: PMC7979620</span></a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/33068227" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 33068227</span></a>]</div></dd></dl><dl class="bkr_refwrap"><dt>108.</dt><dd><div class="bk_ref" id="article-149535.r108">Tang AM, Forrester J, Spiegelman D, Knox TA, Tchetgen E, Gorbach SL. Weight loss and survival in HIV-positive patients in the era of highly active antiretroviral therapy. <span><span class="ref-journal">J Acquir Immune Defic Syndr. </span>2002 Oct 01;<span class="ref-vol">31</span>(2):230-6.</span> [<a href="https://pubmed.ncbi.nlm.nih.gov/12394802" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 12394802</span></a>]</div></dd></dl><dl class="bkr_refwrap"><dt>109.</dt><dd><div class="bk_ref" id="article-149535.r109">Tsiodras S, Mantzoros C, Hammer S, Samore M. Effects of protease inhibitors on hyperglycemia, hyperlipidemia, and lipodystrophy: a 5-year cohort study. <span><span class="ref-journal">Arch Intern Med. </span>2000 Jul 10;<span class="ref-vol">160</span>(13):2050-6.</span> [<a href="https://pubmed.ncbi.nlm.nih.gov/10888979" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 10888979</span></a>]</div></dd></dl><dl class="bkr_refwrap"><dt>110.</dt><dd><div class="bk_ref" id="article-149535.r110">Mitka M. Exploring Statins to Decrease HIV-Related Heart Disease Risk. <span><span class="ref-journal">JAMA. </span>2015 Aug 18;<span class="ref-vol">314</span>(7):657-9.</span> [<a href="https://pubmed.ncbi.nlm.nih.gov/26222872" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 26222872</span></a>]</div></dd></dl><dl class="bkr_refwrap"><dt>111.</dt><dd><div class="bk_ref" id="article-149535.r111">Teeraananchai S, Kerr SJ, Amin J, Ruxrungtham K, Law MG. Life expectancy of HIV-positive people after starting combination antiretroviral therapy: a meta-analysis. <span><span class="ref-journal">HIV Med. </span>2017 Apr;<span class="ref-vol">18</span>(4):256-266.</span> [<a href="https://pubmed.ncbi.nlm.nih.gov/27578404" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 27578404</span></a>]</div></dd></dl><dl class="bkr_refwrap"><dt>112.</dt><dd><div class="bk_ref" id="article-149535.r112">Marcus JL, Chao CR, Leyden WA, Xu L, Quesenberry CP, Klein DB, Towner WJ, Horberg MA, Silverberg MJ. Narrowing the Gap in Life Expectancy Between HIV-Infected and HIV-Uninfected Individuals With Access to Care. <span><span class="ref-journal">J Acquir Immune Defic Syndr. </span>2016 Sep 01;<span class="ref-vol">73</span>(1):39-46.</span> [<a href="/pmc/articles/PMC5427712/" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pmc">PMC free article<span class="bk_prnt">: PMC5427712</span></a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/27028501" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 27028501</span></a>]</div></dd></dl><dl class="bkr_refwrap"><dt>113.</dt><dd><div class="bk_ref" id="article-149535.r113">Kwaku MP, Burman KD. Myxedema coma. <span><span class="ref-journal">J Intensive Care Med. </span>2007 Jul-Aug;<span class="ref-vol">22</span>(4):224-31.</span> [<a href="https://pubmed.ncbi.nlm.nih.gov/17712058" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 17712058</span></a>]</div></dd></dl><dl class="bkr_refwrap"><dt>114.</dt><dd><div class="bk_ref" id="article-149535.r114">Sarlis NJ, Gourgiotis L. Thyroid emergencies. <span><span class="ref-journal">Rev Endocr Metab Disord. </span>2003 May;<span class="ref-vol">4</span>(2):129-36.</span> [<a href="https://pubmed.ncbi.nlm.nih.gov/12766540" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 12766540</span></a>]</div></dd></dl><dl class="bkr_refwrap"><dt>115.</dt><dd><div class="bk_ref" id="article-149535.r115">Lincoff AM, Bhasin S, Flevaris P, Mitchell LM, Basaria S, Boden WE, Cunningham GR, Granger CB, Khera M, Thompson IM, Wang Q, Wolski K, Davey D, Kalahasti V, Khan N, Miller MG, Snabes MC, Chan A, Dubcenco E, Li X, Yi T, Huang B, Pencina KM, Travison TG, Nissen SE., TRAVERSE Study Investigators. Cardiovascular Safety of Testosterone-Replacement Therapy. <span><span class="ref-journal">N Engl J Med. </span>2023 Jul 13;<span class="ref-vol">389</span>(2):107-117.</span> [<a href="https://pubmed.ncbi.nlm.nih.gov/37326322" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 37326322</span></a>]</div></dd></dl><dl class="bkr_refwrap"><dt>116.</dt><dd><div class="bk_ref" id="article-149535.r116">Yuen KCJ, Biller BMK, Radovick S, Carmichael JD, Jasim S, Pantalone KM, Hoffman AR. AMERICAN ASSOCIATION OF CLINICAL ENDOCRINOLOGISTS AND AMERICAN COLLEGE OF ENDOCRINOLOGY GUIDELINES FOR MANAGEMENT OF GROWTH HORMONE DEFICIENCY IN ADULTS AND PATIENTS TRANSITIONING FROM PEDIATRIC TO ADULT CARE. <span><span class="ref-journal">Endocr Pract. </span>2019 Nov;<span class="ref-vol">25</span>(11):1191-1232.</span> [<a href="https://pubmed.ncbi.nlm.nih.gov/31760824" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 31760824</span></a>]</div></dd></dl><dl class="bkr_refwrap"><dt>117.</dt><dd><div class="bk_ref" id="article-149535.r117">Harding JL, Pavkov ME, Magliano DJ, Shaw JE, Gregg EW. Global trends in diabetes complications: a review of current evidence. <span><span class="ref-journal">Diabetologia. </span>2019 Jan;<span class="ref-vol">62</span>(1):3-16.</span> [<a href="https://pubmed.ncbi.nlm.nih.gov/30171279" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 30171279</span></a>]</div></dd></dl></dl></div><div><dl class="temp-labeled-list small"><dl class="bkr_refwrap"><dt></dt><dd><div><p class="no_top_margin">
|
|
<b>Disclosure: </b>Sri Ram Teja Sathi declares no relevant financial relationships with ineligible companies.</p></div></dd></dl><dl class="bkr_refwrap"><dt></dt><dd><div><p class="no_top_margin">
|
|
<b>Disclosure: </b>Catherine Anastasopoulou declares no relevant financial relationships with ineligible companies.</p></div></dd></dl></dl></div></div></div><div class="fm-sec"><h2 id="_NBK599549_pubdet_">Publication Details</h2><h3>Author Information and Affiliations</h3><p class="contrib-group"><h4>Authors</h4><span itemprop="author">Sri Ram Teja T. Sathi</span><sup>1</sup>; <span itemprop="author">Catherine Anastasopoulou</span><sup>2</sup>.</p><h4>Affiliations</h4><div class="affiliation"><sup>1</sup> Einstein Medical center</div><div class="affiliation"><sup>2</sup> Jefferson Einstein Medical Center</div><h3>Publication History</h3><p class="small">Last Update: <span itemprop="dateModified">January 11, 2024</span>.</p><h3>Copyright</h3><div><div class="half_rhythm"><a href="/books/about/copyright/">Copyright</a> © 2025, StatPearls Publishing LLC.<p class="small">
|
|
This book is distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International (CC BY-NC-ND 4.0)
|
|
(<a href="https://creativecommons.org/licenses/by-nc-nd/4.0/" ref="pagearea=meta&targetsite=external&targetcat=link&targettype=uri">
|
|
http://creativecommons.org/licenses/by-nc-nd/4.0/
|
|
</a>), which permits others to distribute the work, provided that the article is not altered or used commercially. You are not required to obtain permission to distribute this article, provided that you credit the author and journal.
|
|
</p></div></div><h3>Publisher</h3><p><a href="https://www.statpearls.com/" ref="pagearea=page-banner&targetsite=external&targetcat=link&targettype=publisher">StatPearls Publishing</a>, Treasure Island (FL)</p><h3>NLM Citation</h3><p>Sathi SRTT, Anastasopoulou C. HIV-Related Endocrinopathies. [Updated 2024 Jan 11]. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2025 Jan-. <span class="bk_cite_avail"></span></p></div><div class="small-screen-prev"></div><div class="small-screen-next"></div></article><article data-type="fig" id="figobarticle149535imagef1"><div id="article-149535.image.f1" class="figure bk_fig"><div class="graphic"><img data-src="/books/NBK599549/bin/graves__orbitopathy.jpg" alt="Image graves__orbitopathy" /></div><div class="caption"><p>Graves orbitopathy Image courtesy S Bhimji MD</p></div></div></article></div><div id="jr-scripts"><script src="/corehtml/pmc/jatsreader/ptpmc_3.22/js/libs.min.js"> </script><script src="/corehtml/pmc/jatsreader/ptpmc_3.22/js/jr.min.js"> </script></div></div>
|
|
|
|
|
|
|
|
|
|
<!-- Book content -->
|
|
|
|
<script type="text/javascript" src="/portal/portal3rc.fcgi/rlib/js/InstrumentNCBIBaseJS/InstrumentPageStarterJS.js"> </script>
|
|
|
|
|
|
<!-- CE8B5AF87C7FFCB1_0191SID /projects/books/PBooks@9.11 portal105 v4.1.r689238 Tue, Oct 22 2024 16:10:51 -->
|
|
<span id="portal-csrf-token" style="display:none" data-token="CE8B5AF87C7FFCB1_0191SID"></span>
|
|
|
|
<script type="text/javascript" src="//static.pubmed.gov/portal/portal3rc.fcgi/4216699/js/3968615.js" snapshot="books"></script></body>
|
|
</html>
|